

Cite this: *Nanoscale*, 2024, **16**, 15928

## Assessing inorganic nanoparticle toxicity through omics approaches†

Yanchen Li,<sup>a</sup> Christopher Vulpe,<sup>b</sup> Twan Lammers<sup>a</sup> and Roger M. Pallares<sup>a</sup>

In the last two decades, the development of nanotechnology has resulted in inorganic nanoparticles playing crucial roles in key industries, ranging from healthcare to energy technologies. For instance, gold and silver nanoparticles are widely used in rapid COVID-19 and flu tests, titania and zinc oxide nanoparticles are commonly found in cosmetic products, and superparamagnetic iron oxide nanoparticles have been clinically exploited as contrast agents and anti-anemia medicines. As a result, human exposure to nanomaterials is continuously increasing, raising concerns about their potential adverse health effects. Historically, the study of nanoparticle toxicity has largely relied on macroscopic observations obtained in different *in vitro* and *in vivo* models, resulting in readouts such as median lethal dose, biodistribution profile, and/or histopathological assessment. In recent years, omics methodologies, including transcriptomics, epigenomics, proteomics, metabolomics, and lipidomics, are increasingly used to characterize the biological interactions of nanomaterials, providing a better and broader understanding of their impact and mechanisms of toxicity. These approaches have been able to identify important genes and gene products that mediate toxicological effects, as well as endogenous functions and pathways dysregulated by nanoparticles. Omics methods improve our understanding of nanoparticle biology, and unravel mechanistic insights into nanomedicine-based therapies. This review aims to provide a deeper understanding and new perspectives of omics approaches to characterize the toxicity and biological interactions of inorganic nanoparticles, and improve the safety of nanoparticle applications.

Received 4th June 2024,  
Accepted 10th August 2024

DOI: 10.1039/d4nr02328e

[rsc.li/nanoscale](http://rsc.li/nanoscale)

### 1. Introduction

In the last few decades, the rise of nanotechnology has sparked important transformations across various fields, including medicine, materials science, energy, and environmental sciences.<sup>1,2</sup> Nanomaterials, with their unique physicochemical properties and large surface-to-volume ratios, exhibit significantly different biological activities and endogenous behaviors compared to bulk materials. These differences have led to the widespread application of nanomedicine in (pre) clinical settings, such as drug delivery, imaging, and diagnostics.<sup>3–5</sup> While this extensive use of nanotechnology has benefited multiple fields, it has also increased human exposure to nanoparticles, raising concerns about potential adverse health effects.

Epidemiological data have demonstrated the harmful consequences of airborne ultrafine particles on human health,<sup>6,7</sup> a finding further corroborated by animal exposure studies.<sup>8</sup> The toxicity of metal and metal oxide nanoparticles is particularly relevant to human health due to their extended residence time and minimal degradation and excretion upon internal exposure.<sup>9</sup> Studies indicate that specific physicochemical properties of nanomaterials, such as particle size, shape, surface charge, chemical composition, and colloidal stability, play a crucial role in defining their nano-bio interactions and potential toxicity.<sup>10–12</sup> Moreover, due to their unique characteristics and interactions within biological systems, nanoparticles can circulate in the bloodstream,<sup>13</sup> and get deposited in multiple organs, including the liver, lungs, spleen, and kidneys, causing non-localized toxicity.<sup>14</sup>


Conventional *in vitro* testing predominantly employs cell-based assays with phenotypic readout parameters, focusing on membrane integrity, apoptosis, cell morphology, and proliferation.<sup>15</sup> While these methods can provide an overview of toxicity, such as the determination of half-maximal inhibitory concentrations (IC<sub>50</sub>), they do not provide mechanistic insights into the effects of the nanoparticles or the responses of the organism to the exposures.<sup>14</sup>

<sup>a</sup>Institute for Experimental Molecular Imaging, RWTH Aachen University Hospital, Aachen 52074, Germany. E-mail: [rmoltopallar@ukaachen.de](mailto:rmoltopallar@ukaachen.de)

<sup>b</sup>Center for Environmental and Human Toxicology, Department of Physiological Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL, 32611, USA

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d4nr02328e>





**Fig. 1** Flow of molecular information within biological systems, and the different omics techniques that can characterize it. Adapted with permission of ref. 20. Copyright Elsevier 2020.

As toxicological assessments advance, the application of omics technologies, such as genomics, transcriptomics, proteomics, and metabolomics (including lipidomics), have emerged as new approaches to gain mechanistic insights into complex interaction mechanisms within biological systems (Fig. 1).<sup>16–23</sup> Research using these technologies has identified key targets and biomarkers associated with nanomaterial toxicity, such as those related to oxidative stress and inflammatory gene activation.<sup>24–26</sup> Furthermore, in addition to providing mechanistic information, omics approaches are also less sensitive to nanoparticle interferences during the screening readout, which is a common issue with traditional toxicological *in vitro* assays due to the inherent characteristics of nanoparticles, which can display strong color, fluorescence, chemical activity, and light scattering.<sup>27</sup>

Taken together, understanding the potential toxicity of nanomaterials, and especially their impact on key organs, requires a comprehensive analysis of their biological activities and interactions. The use of advanced toxicity testing techniques, particularly omics-based approaches, facilitates a more comprehensive assessment of nanomaterial safety. This review article summarizes the various approaches, methods, advantages, and limitations of using omics approaches to assess the toxicity of key inorganic nanoparticles, to elucidate their toxicity mechanisms (or lack thereof) and to ensure their safe application in different fields.

## 2. Omics techniques

In toxicology, omics are used to interpret the response of an organism to an external substance by pooling biomolecules (e.g. DNA, RNA, proteins, and lipids). These profiling techniques are then used to elucidate the molecular mechanisms that result in toxicity. In this section, we provide an overview of the different omics approaches used in the field of toxicology, highlighting the information that is more relevant to the study of nanoparticle toxicity (Fig. S1†). We refer the reader to more

specific literature for a more in-depth description of the distinct omics techniques available.<sup>28</sup>

### 2.1. Genomics and transcriptomics

Genomics and transcriptomics are disciplines that seek to understand the composition, structure, and function of genetic material, providing insights into gene expression patterns and regulatory mechanisms.<sup>29,30</sup> The distinction lies in genomics focusing on the comprehensive study of an organism's genome, while transcriptomics specifically examines sets of RNA transcribed from the genome.<sup>14,29</sup>

Transcriptomics, focused on genome-wide RNA levels, has evolved considerably with the development of approaches such as DNA microarrays, reverse transcription-quantitative real-time polymerase chain reaction (RT-qPCR), and next-generation sequencing (NGS) based RNA sequencing (RNA-seq).<sup>31,32</sup> Transcriptomics can unveil the complex responses of organisms to environmental exposures by profiling gene expression.<sup>33</sup> Moreover, transcriptomics also enables the examination of short non-coding RNAs, which have emerged as potential biomarkers or therapeutic targets due to their dysregulation in diseases.<sup>34–36</sup> Genomics employs genotype arrays,<sup>37</sup> exome sequencing,<sup>38</sup> and NGS of genomic DNA, among others,<sup>39</sup> to discern genetic factors linked to diseases, treatment responses, and future patient prognoses.<sup>40,41</sup>

Taken together, genomic and transcriptomic profiling can assess the impact of nanomaterial exposures on organisms by revealing changes in the genome and gene expression patterns, providing a comprehensive evaluation of adverse effects and molecular mechanisms associated with nanoparticle exposure and toxicity.

### 2.2. Epigenomics

Epigenomics investigates reversible modifications of the DNA or DNA-associated proteins, known as epigenetic modifications.<sup>42</sup> These alterations, including DNA methylation and

histone acetylation, serve as regulators of gene transcription (and, consequently, cellular fate), and are governed by a complex interplay of genetic and environmental factors.<sup>43</sup> Furthermore, there is increasing evidence that suggests that the harmful effects of environmental stressors (including those with nanoparticle form), such as smoking, air pollution, and endocrine disruptors, are mediated *via* epigenetic mechanisms,<sup>44</sup> even in prenatal exposures.<sup>45</sup>

Epigenetic modifications can be identified with multiple technologies, including DNA methylation and histone modification assays, as well as DNA microarrays.<sup>46</sup> As researchers delve into the intersection of epigenomics and nanotoxicology, they are able to understand to what extent nanoparticles (and other nanomaterials) can induce epigenetic modifications, contributing to a more nuanced understanding of the toxicological impact of nanomaterials at the epigenetic level.

### 2.3. Proteomics

Proteomics focuses on the comprehensive study of proteins within biological systems, including protein abundance, modifications, and interactions,<sup>47</sup> which can be later used to discern the cytotoxic effects of a toxicant or toxin or the response of organisms to chemicals.<sup>48,49</sup> Proteomics is primarily explored with mass spectrometry (MS) techniques, which can enable high-throughput analysis of thousands of proteins in complex mixtures.<sup>50</sup> For screening of samples with a smaller number of proteins, antibody microarrays can also be used.<sup>51</sup> Other proteomics methods include phage display<sup>52</sup> and yeast two-hybrid assays<sup>53</sup> which focus on identifying protein interactions. Understanding post-translational modifications is also a key focus of proteomics since they have key roles in signaling, enzyme control, turnover, and cellular structure.<sup>54</sup> For instance, ongoing efforts target genome-level post-translational modification analyses, which exploit techniques such as two-dimensional electrophoresis,<sup>55</sup> fluorescence/stable isotope labeling,<sup>56</sup> and various MS approaches.<sup>57</sup>

Proteomics techniques are also commonly used to characterize the impact of biological environments on the nanoparticles, such as the formation of protein corona. This is a shell made by a mixture of environmental proteins that get adsorbed on nanoparticle surfaces when these are exposed to biological media, changing their physicochemical properties and biological impact.<sup>58</sup> Proteomics studies have identified that nanoparticle features, such as material composition, particle size, and surface charge, strongly affect the protein corona formation and composition.<sup>59–62</sup> These findings are relevant since some studies found that nanoparticles with protein corona have generally less cytotoxicity compared to those without corona.<sup>63–65</sup> In the context of nanoparticle toxicology, proteomics stands as a key tool, providing crucial insights into cellular responses and contributing to advances in our understanding of the intricate interplay between nanoparticles and biological systems.

### 2.4. Metabolomics

Metabolomics focuses on unraveling phenotypic changes induced by chemicals or toxicants through the measurement

of alterations in carbohydrate, lipid, and amino acid patterns, among others. Unlike organism-specific transcriptomics and proteomics, metabolomics lacks a fixed code and encompasses the entire metabolome, analyzed either extracellularly (footprint) or intracellularly (fingerprint).<sup>66</sup> The workflow involves the separation, enrichment, and quantification of metabolites with nuclear magnetic resonance (NMR) or MS approaches. On the one hand, NMR is known for its reliability in detecting various metabolites,<sup>67,68</sup> however, it has limited sensitivity and, usually, it can only identify fewer than 100 metabolites.<sup>69,70</sup> On the other hand, MS-based techniques display higher sensitivity and can quantify hundreds to thousands of metabolites. MS is commonly combined with either gas chromatography (GC) or liquid chromatography (LC) for metabolite separation before identification and quantification.<sup>71–73</sup> Nevertheless, MS techniques can be costly, require complex sample preparation (e.g. tissue extraction), and provide average reproducibility.

Due to the wide variety of potential analytes, metabolomics analyses face several challenges, such as being able to cover broad concentration ranges during the screenings. Furthermore, because metabolites can display rather different chemical structures, their analysis may require the use of different detection techniques.<sup>66</sup> Despite these challenges, the field can provide valuable insights into metabolite functions, being particularly well-suited for toxicological studies.

### 2.5. Lipidomics

Lipidomics is a specialized branch of metabolomics that encompasses membrane-lipidomics and mediator-lipidomics.<sup>20</sup> The former involves the characterization of membrane lipid constituents and their structural aspects, while the latter concentrates on the quantification of low-abundance bioactive lipid species. This dynamic field extensively examines individual lipids and lipid-derived species, delving into their structure, function, and interactions with cellular components such as proteins, other lipids, and metabolites.<sup>74</sup> Research in lipidomics spans diverse biochemical domains, exploring health and disease conditions across various organs, biological tissues, individual cells, and biofluids.<sup>75</sup>

Ultrahigh-performance liquid chromatography–mass spectrometry (UHPLC-MS)<sup>76</sup> is a pivotal tool in lipidomics research, facilitating the rapid and precise lipid profiling in diverse biological samples, which is essential for uncovering disease-related alterations, identifying biomarkers, and studying the impact of nanomaterials on lipid composition and toxicity.<sup>8,77</sup>

## 3. Toxicity of noble metal nanoparticles

Noble metal nanoparticles are among the most widely used nanomaterials, with applications in multiple fields ranging from healthcare to catalysis.<sup>78–81</sup> Noble metal nanoparticles hold localized surface plasmon resonances (*i.e.* collective oscillation of their conduction electrons), which yield unique opto-



electronic properties.<sup>82,83</sup> These plasmon resonances can be tuned by the size and shape of the nanocrystals, and result in strong extinction coefficients, near-field enhancements, and the generation of hot electrons and local heat upon light irradiation. The strong optical properties are commonly used in biosensing (*e.g.* rapid COVID-19 and flu tests),<sup>84</sup> the near-field enhancements are applied in enhanced spectroscopy,<sup>85</sup> the hot-electron generation are exploited in catalysis and semiconductor doping,<sup>86–88</sup> and the local heat generation is clinically being investigated in photothermal ablation of prostate cancer,<sup>89</sup> and is preclinically used for photoacoustic imaging.<sup>90,91</sup> Furthermore, some metal noble nanoparticles are commonly used as antibacterial agents.<sup>92–94</sup> As a result, human exposure to these nanoparticles is increasing over time and needs to be thoroughly understood.

### 3.1. Toxicity of silver nanoparticles (AgNPs)

Due to their unique physicochemical features, which result in strong optical properties and antibacterial effects (among others), AgNPs are commonly used in a wide range of commercial products, ranging from rapid antigen tests (*e.g.* COVID and flu tests)<sup>95,96</sup> to antibacterial materials.<sup>97</sup> The growing use of AgNPs in multiple industries has increased human exposure to these nanoparticles. Hence, a deep understanding of their biological impact is necessary to minimize potential adverse health effects that may originate from their use. It is worth pointing out that ionic and colloidal silver is used as antibacterial agent, especially in burned patients, and silver overload (argyria) is generally considered non-(severely) toxic.<sup>98</sup> Hence, a key question in nanotoxicity that needs to be solved is whether AgNPs behave differently.

**3.1.1. Skin toxicity of AgNPs.** Given that the skin represents one of the primary routes of exposure to nanoparticles,<sup>99</sup> several studies have been conducted to understand the toxicity of AgNPs in different skin models. An early study explored the toxicity of 20 nm bare AgNPs in human dermal fibroblasts fetal (HDFs) using DNA microarrays and RT-PCR.<sup>100</sup> The authors inferred based on gene expression that AgNPs disrupted the cytoskeleton, cellular membrane, and energy metabolism. Furthermore, the nanoparticles also caused DNA damage with cell cycle arrest. These conclusions were further corroborated by a follow-up study that combined proteomics with transcriptomics to analyze AgNP toxicity (in a concentration range between 0 and 100 mg mL<sup>-1</sup>) in HDFs and inferred based on genomic data that treatments with AgNPs disrupted the cytoskeleton, ATP synthesis, and apoptosis.<sup>101</sup> These observations were validated by qualitative cytoskeleton observations and ATP quantification analysis. Transcriptomics profiling identified the dysregulation of key miRNAs that are involved in cytoskeleton dynamics, such as miR-30a and miR-20a. Furthermore, proteomic analysis highlighted proteins involved in the regulation of actin cytoskeleton and the signaling of hepatocyte growth factor receptor pathways. Hence, the multi-omics data collectively suggested that AgNPs induced damage to the HDF cytoskeleton. Other mRNAs and proteins associated with the MAPK signaling pathway, which is

fundamental in apoptosis regulation, were also strongly affected by the AgNP treatments, indicating that the silver colloids might induce apoptosis through the alteration of this pathway. Overall this study highlighted the complexity behind the mechanisms of toxicity associated with bare AgNPs in HDFs. Interestingly, a third study that employed nuclear NMR metabolomics in HaCaT cells (human skin keratinocytes) identified that the dysregulation of the different metabolic pathways could be either mediated or independent of reactive oxygen species.<sup>102</sup> Hence, only in the presence of agents that produce reactive oxygen species, such as hydrogen peroxide, exposures to AgNPs downregulated glycolysis, while the impact of silver colloids on other metabolic pathways, such as glutaminolysis and the Krebs cycle, was independent of reactive oxygen species.

Taken together, these studies with different *in vitro* skin models indicate that exposures to AgNPs seem to disrupt the cytoskeleton and metabolism (including ATP production), and induce apoptosis through the dysregulation of key biological pathways, such as MAPK signaling pathway.

**3.1.2. Pulmonary toxicity of AgNPs.** Due to their small size and ease of getting suspended in air, inhalation is another main route of exposure to nanoparticles and a source of potential toxicity.<sup>103,104</sup> For example, a pioneer study compared the toxicity of AgNPs and silver ions in 2D cell cultures of lung epithelial (A459) cells *via* toxicogenomics.<sup>105</sup> Interestingly, AgNPs dysregulated a greater number of genes compared to silver ions. The authors hypothesized that the greater damage caused by AgNPs was due to their higher uptake *via* endocytosis. Downregulation of key cell cycle genes was observed after AgNP exposures, suggesting their direct interaction with cell cycle-related proteins. Moreover, flow cytometric analysis indicated an increase in S (DNA synthesis) and G2/M (cell growth) cell cycle phases after AgNP exposures, but not with silver ion treatments, suggesting that AgNPs had a more complex effect on cells compared to silver ions. Another study, following up on the biological effect of AgNPs in lung epithelial cells, assessed the impact of nanoparticle size on toxicity.<sup>106</sup> The study found that 100 nm AgNPs did not exhibit cellular toxicity, while 5 nm AgNPs led to an increase in the expression of interleukin-11 and stress-related genes, ultimately resulting in cellular toxicity, likely as a result of their higher uptake due to their smaller size and higher surface-to-volume ratios. This observation highlighted the size-dependent effects of AgNPs on lung epithelial cells, with smaller nanoparticles showing more adverse effects.

**3.1.3. Hepatotoxicity of AgNPs.** Upon systemic administration, nanoparticles circulate through the bloodstream and passively accumulate in well-perfused tissues that are rich in phagocytes.<sup>84,107</sup> Those are (tend to be) characteristics of pathological tissues, such as tumors and inflammation sites, but also of fenestrated organs, such as the liver and spleen. As a consequence, a large proportion of nanoparticles intravenously administered tend to accumulate in the liver, interacting with different hepatic cell populations depending on the nanoparticle characteristics.<sup>108</sup> Consequently, the toxicities of




different nanoparticle types, including AgNPs, have been studied in different hepatic models. For example, similarly to the results observed in lung epithelial cells, a comparative toxicogenomic study between AgNPs and  $\text{Ag}_2\text{CO}_3$  in HepG<sub>2</sub> human hepatocarcinoma 2D cell cultures reported that AgNPs with sizes between 7 and 10 nm and coated with polyethylenimine exhibited substantial cytotoxicity at high doses ( $>1.0 \text{ mg L}^{-1}$ ), while  $\text{Ag}_2\text{CO}_3$  had no measurable effects at the same tested doses.<sup>109</sup> The AgNPs also induced irregular cell shapes and the formation of micronucleus, suggesting chromosomal damage by AgNPs compared to the silver salt treatments. It is worth noting, however, that toxicity studies strongly depend on the model used. For instance, a proteomic study using common carp as a model organism identified that both AgNPs and  $\text{AgNO}_3$  induced mitochondrial toxicity in the gills through the dysregulation of different proteins, including 39S ribosomal protein L4, L22, L43 and 28S ribosomal protein S22, S29 (Fig. 2A–C).<sup>110</sup> These differences highlight the model-dependent nature of toxicity studies and the need to consider various factors when interpreting the results. Nevertheless, more studies suggest that AgNPs and silver ions interact differently with endogenous targets, leading to the dysregulation of distinct pathways and biological functions. For example, in a toxicogenomic study using RNA-Seq of human hepatocellular carcinoma cells, it was observed that  $\text{AgNO}_3$  affected various pathways related to DNA damage and the cell cycle.<sup>111</sup> In contrast, AgNPs disrupted pathways associated with cell regulation, survival, and the development of diseases like liver fibrosis and tumors. These consistent patterns suggest that

AgNPs and silver ions have unique interactions with biological systems, leading to distinct outcomes in different models.

Another study employed a shotgun tandem MS approach to assess the impact of 92 nm AgNPs (coating not reported) on human hepatoma (HepG2) cells.<sup>77</sup> Their main conclusion was that treatments with AgNPs resulted in substantial alterations in a wide variety of phosphatidylcholine species. This observation suggested that the toxicity induced by nanoparticles primarily arose from inflammatory processes. It is essential to note, however, that these studies were conducted in liver cancer cells and the toxicogenomic information acquired in these studies may not be entirely applicable to a healthy liver. To date, toxicogenomic studies that use primary cells are extremely rare and most *in vitro* toxicity studies rely on pathological cells.

**3.1.4. Toxicity of AgNPs in the digestive system.** In addition to inhalation, exposure to bare skin, and systemic administration, another potential exposure route to nanoparticles is ingestion and absorption through the gastric system. Consequently, several studies have assessed the toxicity of AgNPs in different digestive system models. For instance, a proteomics study explored the toxicity of 30 nm citrate-coated AgNPs in adenocarcinoma CaCo-2 cells using 2D gel and MS. Based on the proteomics data, the authors inferred that the AgNP treatments led to alterations in several key biological processes, including cell cycle, cell morphology, cellular function, and maintenance.<sup>112</sup>

Beyond its role in food digestion and nutrient extraction, the digestive system also acts as a host environment to a wide



**Fig. 2** Toxicological effects of AgNPs and PdNPs. Comparison between the toxicological effects of AgNPs and silver nitrate ( $\text{AgNO}_3$ ) in gills of common carp, including (A) principal component analysis, (B) Venn diagrams plot, and (C) hierarchical clustering of different dysregulated proteins. The hierarchical clustering also includes the functional labels associated with the dysregulated proteins. Adapted with permission of ref. 110. Copyright Elsevier 2022. Functional groups associated with (D) down- and (E) up-regulated genes by PdNP treatments in human ovarian cancer cells. Adapted with permission of ref. 141. Copyright MDPI (Basel, Switzerland) 2019.



range of microorganisms, including bacteria, archaea, fungi, and viruses, which have a broad impact in many health-related functions, such as resistance to pathogens, metabolism of dietary and pharmaceutical compounds, and control of the immune system, among others.<sup>113,114</sup> Therefore, the ingestion of nanoparticles has the potential to also disrupt the normal functioning of the gut microbiota. In this context, a recent transcriptomics study, which involved RNA-Seq and RT-PCR, assessed the *in vivo* effects of AgNPs on the transcriptome and gut microbiota.<sup>115</sup> Notably, the AgNP treatments induced immunotoxicological changes at both the molecular and microbiome levels, which were associated with stress and colon inflammation.

**3.1.5. Teratogenic toxicity of AgNPs.** As a response to the concerns surrounding the potential toxicity of chemicals during pregnancy and embryo development, several studies have investigated the impact of AgNPs on various embryo models. For example, a toxicogenomic study using DNA arrays in zebrafish embryos at 24 hours post-fertilization observed that AgNPs disrupted erythropoiesis primarily due to the nanoparticle structure since silver ions under the same conditions had low toxicological impact.<sup>116</sup> Another toxicogenomic study, which explored AgNP toxicity in zebrafish embryos *via* RNA-seq, revealed that AgNPs induced oxidative stress and mitochondrial dysfunction, contributing to embryonic developmental toxicity, further corroborating the potential risks associated with AgNP exposures during embryonic development.<sup>117</sup>

### 3.2. Toxicity of gold nanoparticles (AuNPs)

AuNPs are nanomaterials with unique optoelectronic properties, which originate from localized surface plasmon resonances.<sup>118</sup> These properties depend on the size and morphology of the nanoparticles,<sup>119–122</sup> and result in strong extinction coefficients, intense near-field enhancements, and large photothermal conversion effects.<sup>123</sup> As a result, AuNPs are commonly used in rapid antigen tests for COVID-19 and flu diagnosis and are being (pre)clinically explored in multiple biosensing assays<sup>78</sup> and therapeutic/theranostic formulations.<sup>89,124,125</sup> Furthermore, the light-excitation of the localized surface plasmon resonances results in the generation of hot electrons, which can be exploited for catalysis and doping of semiconductors.<sup>126</sup> The ever-growing use of AuNPs requires a deep understanding of their biological impact to ensure their safety.

Although their toxicological profile has not been as thoroughly studied through omics approaches as in the case of AgNPs, there are a couple of toxicomics studies focused on AuNPs that are worth mentioning. One study compared the toxicological profile of AuNPs and AgNPs on human dermal fibroblasts using RNA-Seq and RT-PCR.<sup>127</sup> Notably, at 200  $\mu$ M, AuNPs were not cytotoxic, despite dysregulating the expression of mRNAs associated with cell cycle, ATP synthesis inhibition, cytoskeleton, and apoptosis. In contrast, AgNPs did cause significant cytotoxicity due to the generation of larger amounts of reactive oxygen species in comparison to AuNPs.

As previously mentioned, several gold nanoformulations are currently being explored in clinical studies.<sup>89</sup> A therapeutic approach that relies on AuNPs is photothermal therapy, where solid tumors and atherosclerosis plaques are ablated *via* the high photothermal conversion efficiency of AuNPs, which concentrate the thermal ablation effect only on the surroundings of the irradiated nanoparticles, providing good therapeutic selectivity. While many preclinical and a few clinical studies have explored the therapeutic benefits of AuNP-based photothermal therapy, only a few have focused on the underlying biological mechanisms. A noteworthy exception is a study where high-resolution LC-MS was used to characterize the impact of photothermal therapy with gold nanorods (AuNRs) on lung cancer cells (A549).<sup>128</sup> AuNRs are nanocrystals that absorb light in the near-infrared,<sup>129–131</sup> where light penetrates deeper into the tissue.<sup>132</sup> The metabolomic data indicated that AuNR-based photothermal treatment exerted toxicity by dysregulating metabolites that contained 18-hydroxyoleate, beta-alanopine and *cis*-9,10-epoxystearic acid, and phosphorylcholine.<sup>128</sup> Several key metabolic pathways were also affected by the photothermal therapy, including those associated with cutin, suberine, and wax biosynthesis, pyruvate and glutamic acid synthesis, and choline metabolism. Taken together, this approach provides a deeper understanding of the mechanisms behind treatment-related cytotoxicity, complementing the conventional focus on macroscopic nanoparticle toxicity.

### 3.3. Toxicity of palladium nanoparticles (PdNPs)

Despite its high material costs, palladium is commonly used as a catalytic material. When the size of bulk palladium is reduced to the nanoscale, its catalytic activity is enhanced because of the higher surface-to-volume ratio of the nanoparticles. Hence, PdNPs hold significant importance in organic synthesis (e.g. catalyzing carbon–carbon bond forming reactions, such as Suzuki or Heck couplings),<sup>133</sup> in the degradation of harmful substances in environmental applications,<sup>134</sup> and in conducting materials and printed electronic devices.<sup>135</sup> Furthermore, PdNPs may play an important role in hydrogen storage and generation,<sup>136</sup> which is vital for the development of hydrogen energy technology. Additionally, PdNPs display strong photothermal capabilities being preclinically used in photoacoustic imaging<sup>137–139</sup> and photothermal therapy.<sup>140</sup>

In the field of nanotoxicology, various studies have explored the effects of PdNPs using omics approaches. For instance, one study employed transcriptomics (*via* RNA-Seq) to analyze the impact of PdNPs on human ovarian cancer cells (SKOV3) (Fig. 2D).<sup>141</sup> The study reported that PdNPs primarily downregulated genes associated with nucleosome assembly, telomere organization, and DNA chromatin silencing. Among these processes, nucleosome assembly was the most significantly affected. Furthermore, RNA-seq analysis also demonstrated that the PdNP treatments triggered epigenetic changes that were associated with cell apoptosis. Another transcriptomics study investigated the accumulation of Pd-doped polystyrene nanoparticles in earthworms and its toxic effects.<sup>142</sup> The study revealed that both positively and negatively surface-charged



nanoparticles could accumulate and move within earthworms, leading to growth inhibition and pathological abnormalities. Positively charged nanoparticles exhibited higher cytotoxicity, likely due to their propensity to form larger aggregations at lower pH, facilitating cellular uptake and apoptosis induction. Gene expression analysis highlighted a more significant impact of positively charged nanoparticles compared to negatively charged ones in both low-dose (0.3 mg kg<sup>-1</sup>) and high-dose (3 mg kg<sup>-1</sup>) treatments. Additionally, a proteomics study using western blot techniques identified that PdNPs inhibit cell growth in various cell lines (*e.g.* Rat-1 rat embryo fibroblasts, CaCo-2 colon adenocarcinoma cells, and HaCaT keratinocyte cells), induce DNA damage, and impact the expression of key cell cycle regulatory proteins, all without triggering apoptosis or oxidative stress.<sup>143</sup> These studies collectively contribute to a better understanding of the biological impact (in different biological systems) of PdNPs, which are numerous and diverse.

#### 3.4. Toxicity of tungsten nanoparticles (WNPs)

Compared to their gold and silver counterparts, WNPs have relatively fewer uses. However, as a result of recent advances in industrial technologies combined with tungsten's high plasticity, high melting point, and electron emission ability, WNPs and their derivatives have found niche applications in electronics,<sup>144</sup> and coatings and films,<sup>145</sup> as well as in the nuclear industry.<sup>146</sup> Regarding their toxicity, a transcriptomics study assessed the biological impact of tungsten boride nanoparticles (WBNPs) in HPAEpiC cells (human lung alveolar epithelial cells).<sup>147</sup> The study concluded that WBNPs can modulate cytokine/chemokine metabolism, affect angiogenesis, and impede migration/invasion of cancer cells by activating specific genes, such as DACH1, COL3A1, and FOS.

#### 3.5. Toxicity of platinum nanoparticles (PtNPs)

In recent years, PtNPs have been increasingly explored in the chemical industry and automotive sector due to their catalytic features.<sup>148–152</sup> Additionally, PtNPs have found some applications in the (preclinical) biomedical field, serving as diagnostic mediators, components of medical implants, drug delivery vehicles, and agents for photothermal therapy.<sup>153,154</sup>

Regarding their toxicity, a transcriptomics study evaluated the biological impact of anisotropic lycopene-derived PtNPs on human acute monocytic leukemia (THP-1) cells.<sup>155</sup> The study found that PtNPs (in a concentration range between 0 and 12 mM) induced dose-dependent cytotoxicity, oxidative stress, and apoptosis. The underlying mechanisms of toxicity were primarily associated with changes in gene expression related to protein misfolding, mitochondrial function, protein synthesis, inflammatory response, and transcriptional regulation.

## 4. Toxicity of metal oxide nanoparticles

Metal oxide nanoparticles are a heterogeneous group of nanocrystals that are widely produced and used because of their

unique electronic, magnetic, and/or chemical properties.<sup>156</sup> Some of the most relevant metal oxide nanoparticles include wide bandgap semiconducting materials (TiO<sub>2</sub>, CeO<sub>2</sub>, ZnO) and magnetic crystals (Fe<sub>2</sub>O<sub>3</sub> and Fe<sub>3</sub>O<sub>4</sub>). These unique characteristics can be controlled by nanocrystal engineering and endow a wide range of applications, such as clinical imaging, gas sensing, and catalysis.<sup>157–160</sup>

#### 4.1. Toxicity of titania nanoparticles (TiO<sub>2</sub>NPs)

TiO<sub>2</sub>NPs exhibit strong ultraviolet (UV) absorption capabilities and resilience to radiation damage.<sup>161–163</sup> As a consequence, they are prevalently employed as UV-blocking agents in sunscreen formulations as well as thickening agents in cosmetics.<sup>164</sup> Furthermore, TiO<sub>2</sub>NPs, especially in the anatase form, display photocatalytic activity under UV irradiation. Consequently, titania colloids have become important in key industrial processes, such as photocatalysis, solar energy harnessing, and air and water purification.<sup>165–168</sup> The versatility and widespread use of TiO<sub>2</sub>NPs, particularly in skin cosmetics, require a deep understanding of their toxicity and biological impact.

**4.1.1. Skin toxicity of TiO<sub>2</sub>NPs.** Because TiO<sub>2</sub>NPs are commonly used in skin cosmetics, there have been concerns regarding their impact on health, even in the absence of UV irradiation. Hence, a pioneer toxicogenomic study assessed the impact of ultrafine TiO<sub>2</sub>NPs in human keratinocytes without UV illumination.<sup>169</sup> Notably, although no significant ROS-associated oxidative damage was observed, TiO<sub>2</sub>NPs without illumination affected the cell-matrix adhesion of keratinocytes, leading to extracellular matrix remodeling. A recent study that utilized a multi-omics approach combined with stable isotopic labeling of amino acids provided further insights into the toxicity of titania colloids in skin cells.<sup>170</sup> In this study, TiO<sub>2</sub>NPs did not significantly induce cell apoptosis, however, the colloids promoted cell cycle arrest in the S-G2/M phase, which was corroborated by RT-qPCR. Furthermore, the disruption of proteins that play a key role in cell cycle regulation, such as CDK2, CCNA1, and CCNB1, were identified by proteomics, providing further insights into the toxicity mechanisms of titania colloids.

**4.1.2. Pulmonary toxicity of TiO<sub>2</sub>NPs.** Various studies have examined TiO<sub>2</sub>NP toxicity in different lung models since inhalation is one of the main exposure routes to nanoparticles. For example, an *in vivo* and *in vitro* study assessing the biological effects of inhaled 21 nm TiO<sub>2</sub>NPs in mice *via* toxicogenomics and toxicoproteomics identified changes in several inflammatory mediators at both the mRNA and protein levels in a dose- and time-dependent manner in the lungs.<sup>171</sup> Notably, even though no neutrophil influx was observed at low TiO<sub>2</sub>NP doses, changes in genes and proteins associated with inflammation were detected. Furthermore, disruptions in the expression of genes related to ion homeostasis and muscle function were also identified, which together with extended nanoparticle exposures could potentially lead to fibrosis, asthma, and lung cancer. These results were consistent with a follow-up study that identified strong dysregulation of genes



associated with immune/inflammatory and apoptotic pathways in the lungs of mice that were exposed to 6 nm  $\text{TiO}_2$  NPs.<sup>172</sup>

The strong biological impact of titania nanocrystals in the lungs of mice was later also observed at the epigenetic level.<sup>173</sup>  $\text{TiO}_2$  NP exposures caused changes in DNA methylation particularly in the promoter regions of genes associated with inflammation and fibrosis, suggesting that abnormal DNA methylation has the potential to be used as biomarkers for pulmonary disease development. Notably, the same study observed that younger mice (5-week-old) displayed greater sensitivity to  $\text{TiO}_2$  NP exposure than older mice (10-week-old) did, as observed by increased methylation, altered gene promoters, and up-regulation in cancer pathways, ultimately resulting in increased pulmonary inflammation and fibrosis. Consistently, a subsequent study identified that exposures to  $\text{TiO}_2$  NPs, even at concentrations well below sublethal levels ( $0.5 \mu\text{g mL}^{-1}$ ), led to significant changes in DNA methylation,<sup>174</sup> indicating that even minimal exposure to these nanoparticles can induce adverse epigenetic effects.

**4.1.3. Hepatotoxicity of  $\text{TiO}_2$  NPs.** Although conventional transcriptomics preferentially quantify the expression of mRNA, some alternative toxicological methods profile other types of RNA. For example, long non-coding RNAs (lncRNAs) are oligonucleotides without protein-coding functions that are involved in transcriptional and epigenetic regulation.<sup>175,176</sup> A recent study explored the toxicity of  $\text{TiO}_2$  NPs in human hepatoma HepG2 cells by characterizing lncRNA expression *via* RNA-Seq and RT-PCR (Fig. 3A–C).<sup>177</sup> The authors identified that  $\text{TiO}_2$  NPs disrupted the expression of specific lncRNAs associated with the Hedgehog signaling pathway and the glutamatergic synapse, ultimately contributing to hepatotoxicity. Moreover, the study identified correlations between the changes in lncRNAs and mRNAs, which suggested a potential epigenetic mechanism behind the hepatic toxicity induced by the nanoparticles.

#### 4.2. Toxicity of zinc oxide nanoparticles (ZnONPs)

In the last two decades, ZnONPs have become widely used in multiple industries because of their excellent optoelectronic properties, stability, and perceived low toxicity.<sup>178</sup> For example, ZnONPs are commonly employed in the manufacturing of sunscreens and cosmetics, as they can effectively block UV radiation.<sup>164,179</sup> Additionally, ZnONPs are utilized in the development of antibacterial agents<sup>180</sup> and as key components in electronic devices and sensors.<sup>181</sup> Due to the widespread applications of ZnONPs, some recent studies have focused on characterizing their toxicological profile through omics approaches, aiming to gain a better understanding of their biological effects and potential uses.

**4.2.1. Pulmonary toxicity of ZnONPs.** Despite being commercially used in multiple products, inhaled ZnONPs are known to induce metal fume fever and systemic inflammatory responses in humans.<sup>182,183</sup> These acute phase responses present serious cardiovascular risks. Taking this into consideration, a genomic and proteomic study aimed to further understand the ZnONP-induced acute phase responses in mice.<sup>184</sup> Two types of nanoparticles, namely uncoated and triethoxycya-


prylsilane-coated ZnONPs, were explored. As solely sub-lethal nanoparticle doses were investigated, only weak non-dose-dependent toxicogenomics effects were identified. Hence, from a genomic point of view, both nanoparticle types caused similar effects, disrupting genes related to circadian rhythm signaling, protein ubiquitination pathway, AMPK signaling, and unfolded protein responses. Proteomics further validated these findings by detecting levels of Serum Amyloid A3 in bronchoalveolar lavage fluid. The main difference between uncoated and coated ZnONPs was the disruption of genes associated with cell cycle G2M damage checkpoint regulation pathway, and functions associated with cell cycle progression, chromosome segregation, and alignment by the former.

**4.2.2. Hepatotoxicity of ZnONPs.** Another study delved into ZnONP toxicity both *in vitro* and *in vivo*, characterizing its impact on the liver.<sup>185</sup> The RNA-seq results demonstrated that despite affecting similar biological functions and components in hepatic cells (HepG2), including immune system processes and membrane parts, ZnONPs caused a greater level of gene expression upregulation and downregulation, particularly in certain functions, such as biological mineralization and cell killing, compared to (non-nano) ZnO powder. Consequently, ZnONPs also induced greater cell inactivation, oxidative stress, mitochondrial damage, and intracellular calcium overload than their non-nano counterparts did. Similarly, in rats, ZnONPs caused more pronounced liver damage, with elevated aspartate aminotransferase and alanine aminotransferase levels, reduced antioxidant capacity, and more severe histopathological damage compared to ZnO powder.

In a metabolomics study, male and female zebrafish were exposed to various concentrations of ZnONPs (Fig. 3D).<sup>186</sup> Their livers were then subjected to metabolome analysis and energy metabolism assessment. The findings indicated that sub-chronic ZnONP exposures reduced the tricarboxylic acid cycle rate and oxidative phosphorylation, leading to ATP loss and energetic stress in both genders. Females compensated by increasing the fatty acid and amino acid metabolisms, while males solely adjusted their amino acid metabolism. Interestingly, this study highlighted several gender-dependent (in zebrafish) adaptative metabolic responses to mitigate disruptions caused by ZnONP exposures.

**4.2.3. Toxicity of ZnONPs to phagocytes.** Phagocytes are key immune system components that determine the endogenous fate of nanoparticles since they participate in the clearance and biodistribution of particulates.<sup>187</sup> From the different types of phagocytes, macrophages are among the primary cells that process nanoparticles, mediating in the host immunological and inflammatory responses to nanomaterials. Hence, it is important to characterize the interaction between nanoparticles and phagocytes to fully understand the biological impact of the former. A recent study exploited sequencing and proteomics to understand the impact of sub-lethal doses of ZnONPs and derivatives ( $\text{ZnFe}_2\text{O}_4$ ) on rat alveolar macrophages (NR8383).<sup>188</sup> Genes encoding metallothioneins, a low molecular weight protein family that binds to heavy metals, were overexpressed after exposures to both particles. Furthermore,





**Fig. 3** Toxicological profile of  $\text{TiO}_2$  NPs based on lncRNA expression alterations in HepG2. (A) Volcano plot highlighting up-regulated and down-regulated lncRNAs, (B) histogram with classification of dysregulated lncRNAs, and (C) heat map and cluster analysis of dysregulated lncRNAs after exposure to  $\text{TiO}_2$  NPs at concentrations of 0 and  $100 \mu\text{g mL}^{-1}$ . Adapted with permission of ref. 177. Copyright MDPI (Basel, Switzerland) 2022. (D) Metabolomics analysis of zebrafish liver following exposures of 0 or  $500 \mu\text{g L}^{-1}$  ZnONPs or equivalent dose of zinc salt ions. Adapted with permission of ref. 186. Copyright Elsevier 2022.

EIF2 signaling, which is involved in protein homeostasis, was the main disrupted pathway. Proteomics characterization carried out with MS highlighted protein homeostasis and cholesterol biosynthesis as the main affected biological functions. Taken together, toxicogenomics and toxicoproteomics identified protein and lipid homeostasis as the main functions disrupted by the nanoparticles.

#### 4.3. Toxicity of superparamagnetic iron oxide nanoparticles (SPIONs)

SPIONs are iron oxide colloids that display unique magnetic properties which combined with their biocompatibility have resulted in their use in different biomedical applications.<sup>189–191</sup> For instance, SPIONs display large magnetic moments that alter the transverse relaxation times ( $T_2$ ) of water protons, decreasing their signal intensity in magnetic

resonance imaging (MRI). Hence, in 1996, a SPION-based formulation (ferumoxide) was clinically approved by the US Food and Drugs Administration as an MRI contrast agent for the detection of liver lesions.<sup>107</sup> Since then, multiple formulations have been developed for the imaging of other diseases, such as atheroma. Even though many of those diagnostic applications were later discontinued in favor of gadolinium-based contrast agents, SPIONs are still being clinically used for specific applications, including iron replacement therapy in anemic patients, imaging of tumor-associated macrophages, and identification of sentinel lymph nodes.<sup>107</sup> Furthermore, a clinical trial has recently started to evaluate SPION-based magnetic hyperthermia to treat advanced pancreatic cancer patients. Beyond therapeutics and diagnostics, the magnetic properties of SPIONs are commonly used for magnetic-based separations, such as in water purification<sup>192</sup> and pollutant removal.<sup>193</sup>



Although SPIONs are generally perceived as biocompatible, there have been concerns regarding their biological impact (e.g. DNA damage, oxidative stress, and epigenetic alterations) under specific conditions and formulations.<sup>194</sup> Thus, to better understand their endogenous behavior, a recent study explored the epigenetic effects of SPIONs coated with citric acid in human submandibular gland cells.<sup>195</sup> Through a combination of colorimetric assays and RT-PCR, the authors concluded that exposures to citric acid-coated SPIONs induced significant alterations in DNA methylation and histone acetylation, which, notably, did not impact cell viability.

Although the adsorption of lipids and proteins onto the surface of nanoparticles has long been known, it was not until the last decade that its impact on nanoparticle behavior *in vivo* started to be understood.<sup>196</sup> In a comprehensive study, researchers exploited proteomic and lipidomic analyses, including LC-MS and a multiple reaction monitoring profiling method, to investigate the formation of protein and lipid corona on 20 nm SPIONs and to explore how this biocorona affects cellular interactions and toxicity.<sup>197</sup> To achieve this, the nanoparticles were exposed to isolated bronchoalveolar lavage fluids from both healthy and metabolic syndrome mouse models. The SPIONs exposed to metabolic syndrome samples were taken up by macrophages to a greater extent than the SPIONs exposed to healthy fluids. Notably, different protein and lipid profiles were identified on the surface of the nanoparticles exposed to the distinct fluids through proteomic and lipidomic analyses. This observation suggested that metabolic syndrome conditions promote protein and lipid corona composition changes in bronchoalveolar lavage fluid, ultimately impacting nanoparticle interactions, which may contribute to the development of acute pulmonary inflammatory responses.

#### 4.4. Toxicity of ceria nanoparticles (CeO<sub>2</sub>NPs)

CeO<sub>2</sub>NPs are prized for their rich redox behavior, as cerium can easily shift between +3 and +4 oxidation states, and can act as oxidation switches.<sup>198</sup> Thus, CeO<sub>2</sub>NPs are being exploited to counteract oxidative stress by scavenging reactive oxygen species,<sup>199</sup> to serve as core components in biosensors for biomolecule detection,<sup>200</sup> to purify wastewater and exhaust gases,<sup>201</sup> to act as catalysts in various reactions,<sup>202,203</sup> and to function as electrolyte materials in fuel cells.<sup>204</sup>

Because CeO<sub>2</sub>NPs (and other metal oxide nanostructures such as cobalt oxide nanoparticles, CoONPs) are used in automotive exhaust catalysts, there are concerns regarding their release in air and potential inhalation. A toxicogenomics study explored the biological effects of both CeO<sub>2</sub>NPs and CoONPs in bronchial and alveolar epithelial cells, two of the main lung cell types that interact with airborne particulates.<sup>205</sup> The study focused on understanding inflammatory responses since these cells can produce pro-inflammatory mediators. Notably, although CeO<sub>2</sub>NPs disrupted the expression of a larger number of genes, CoONPs had a more pronounced impact on immune system-related processes.

The onset of immune responses by inhaled CeO<sub>2</sub>NPs was further demonstrated *in vivo* in male Sprague-Dawley rats

through lipidomics and transcriptomics.<sup>8</sup> The aerosolized 40 nm CeO<sub>2</sub>NPs triggered inflammation and immune responses, not only in the lungs but in the liver and kidneys, with significant changes in inflammation markers and gene expression, as confirmed by transcriptomics. Moreover, lipidomics profiling of lung tissue further revealed changes to minor lipid species, implying specific rather than general cellular effects. Notably, these inflammatory effects triggered by the CeO<sub>2</sub>NPs were greater than those observed in toxicomics studies using micron-sized ceria aerosols, corroborating the larger biological reactivity of materials at the nanoscale.

#### 4.5. Toxicity of other metal oxide nanoparticles

Beyond the cases discussed above, several studies have examined the toxicity of other metal oxide nanoparticles. For instance, a study explored the toxicological profile of catalytic vanadium oxide nanoparticles (V<sub>2</sub>O<sub>5</sub>NPs) through high-resolution metabolomics in human airway epithelial cells (BEAS-2B).<sup>206</sup> Even at non-cytotoxic doses, V<sub>2</sub>O<sub>5</sub>NPs induced dose-dependent responses in several major metabolic pathways, including the metabolism of amino sugars, amino acids, fatty acids, carnitine, and nucleotides, some of which have been previously linked to human lung diseases.<sup>207</sup>

In a separate study, the toxicity of low doses (0.5 µg Ni mL<sup>-1</sup>) of nickel oxide nanoparticles (NiONPs) and nickel nanoparticles (NiNPs), which are used in electronics and catalysis,<sup>208</sup> were screened through RNA-Seq in human lung cells (BEAS-2B) after prolonged exposures (six weeks). Both NiONPs and NiNPs caused DNA strand breaks, which were consistent with exposures to nickel chloride salts.

A comprehensive study combining genomics, transcriptomics, and metabolomics investigated the impact of gadolinium oxide nanoparticles (GdONPs) on 4T1 breast cancer cells.<sup>209</sup> The research demonstrated that GdONPs induced apoptosis in 4T1 cells by significantly increasing the production of reactive oxygen species, leading to enhanced DNA damage within the cells. These results were consistent with a study that followed a similar approach and explored the effects of manganese oxide nanoparticles (Mn<sub>3</sub>O<sub>4</sub>NPs) at a concentration of 100 µg mL<sup>-1</sup> on rat type II alveolar epithelial cells.<sup>210</sup> The authors proved that Mn<sub>3</sub>O<sub>4</sub>NPs also induced an increase in reactive oxygen species, leading to significant oxidative stress, which triggered the apoptosis of the rat type II alveolar epithelial cells. Other heavy metal oxide nanoparticles, such as molybdenum dioxide nanoparticles (MoO<sub>2</sub>NPs), have also shown to induce significant toxicity, such as in the liver, through oxidative stress and inflammation, leading to notable changes in the expression of inflammation markers and genes.<sup>211</sup>

### 5. Toxicity of other inorganic nanoparticles

#### 5.1. Toxicity of quantum dots

Quantum dots are semiconductor nanocrystals that display shape- and size-dependent optical and electronic properties,

which are in between those of bulk semiconductors and discrete atoms.<sup>212</sup> For instance, as the size of quantum dots increases (from 2 to 6 nm), their emissions red-shift to longer wavelengths. Quantum dots are widely used in optoelectronic devices, such as light-emitting diode (QLED) screens and lasers.<sup>213</sup> Furthermore, they have also been explored as optical probes in preclinical imaging.<sup>214</sup> It is worth mentioning that the Nobel Prize in Chemistry 2023 was awarded to Professors Ekimov, Brus, and Bawendi for the discovery and synthesis of quantum dots.<sup>215–217</sup>

A proteomic study explored the toxicity of CdTe quantum dots in human monocytes THP-1 and compared it to the toxicity of AuNPs and copper oxide nanoparticles (CuONPs).<sup>218</sup> Despite showing similar overall toxicity, CdTe induced the strongest proteomic responses by down-regulating topoisomerase, enzymes that catalyze changes in the topological state of DNA. The authors hypothesized that CdTe may affect the alkylation of DNA or affect chromatin-related proteins, which would be consistent with the cytotoxic mechanisms associated with Cd<sup>2+</sup>.

## 5.2. Toxicity of silica nanoparticles (SiO<sub>2</sub>NPs)

Silicon is one of the most abundant elements on Earth's crust, and nanoparticles made of its oxide have found multiple industrial applications, ranging from fining agents for beverages to cosmetics.<sup>219</sup> SiO<sub>2</sub>NPs can be either crystalline or amorphous. While their molecular composition is the same, both crystalline and amorphous structures can display different properties. For example, some crystalline SiO<sub>2</sub>NPs possess porous with diameters ranging from 2 to 100 nm that can be filled with different therapeutic and diagnostic agents.<sup>215–217</sup> Hence, numerous nanomedicines based on (meso)porous SiO<sub>2</sub>NPs are currently being explored in clinical trials for sentinel lymph node mapping and oral drug delivery, among others.<sup>220</sup> The increasing use of SiO<sub>2</sub>NPs in biomedical applications and their widespread presence in the food and cosmetic industry requires a thorough characterization of their toxicity.

In the last years, there has been an increasing concern about the impact of nanoparticles on male fertility.<sup>221,222</sup> In this context, a genomic study explored the toxicity of SiO<sub>2</sub>NPs in murine spermatocyte cells.<sup>223</sup> SiO<sub>2</sub>NP treatment dysregulated 15 significant miRNAs, which were associated with DNA replication and fatty acid metabolism, identifying the origin of SiO<sub>2</sub>NPs in spermatocyte cells.

In a separate study, researchers adopted a multifaceted approach by combining proteomics and metabolomics to screen the metabolic disturbances induced by SiO<sub>2</sub>NPs in liver cells (Fig. 4).<sup>224</sup> Through proteomics analysis, they unveiled the aberrant expression of key proteins, including RPL3, HSP90AA1, SOD, PGK1, GOT1, and PNP, which were associated with protein synthesis, folding, oxidative stress, and overall metabolism. Complementing these findings, metabolomics analysis provided further evidence of disrupted metabolic pathways, encompassing glucose metabolism, amino acid metabolism, and nucleotide metabolism. These results high-

lighted the strong impact of SiO<sub>2</sub>NPs on cellular metabolic processes.

## 6. Lessons learned and recommendations

### 6.1. Lack of universal toxicity rules

It is challenging to identify general rules that define the toxicity of nanoparticles, since they come in all sorts of shapes and forms, and can behave differently. For instance, nanoparticles can display sizes ranging from a few nanometers, which result in rapid nanoparticle excretion through renal pathways,<sup>225</sup> to several hundreds of nanometers, which yield nanoparticles with large accumulation in fenestrated organs, such as the liver and spleen.<sup>108,109</sup> A wide variety of core materials are used to synthesize nanoparticles, which include noble metals, metal oxides, and semiconductors, to name a few (Table S1†). Some of these materials can be degraded or excreted by the body,<sup>110</sup> while others cannot and tend to accumulate in tissues for prolonged periods of time.<sup>108,109</sup> Moreover, some of these materials can display inherent cytotoxicity, *e.g.* *via* reactive oxygen species production,<sup>226</sup> or promote acute immune responses.<sup>227</sup> Notably, some materials may also possess different properties depending on whether they are found in nanoparticulate form or ionic form, further complicating their toxicity assessment.<sup>109</sup> Nanoparticles may have coating or ligand shell on their surface, which can be engineered to improve their colloidal stability or to recognize specific targets.<sup>228</sup> The shell characteristics, such as size and charge, strongly affect the fate and toxicity of the nanoparticles both *in vitro* and *in vivo*.<sup>229,230</sup> For example, nanoparticles with strong positive charge tend to display higher cellular uptake *in vitro*,<sup>231</sup> but also nanoparticles with strong surface charges tend to adsorb large amounts of plasma components on their surface, which can be recognized by phagocytes, yielding nanoparticles with short circulation times in the bloodstream.<sup>232</sup>


### 6.2. The role of protein corona

In the last decade, the concept of protein (and lipid) corona has emerged in the field of nanoscience. When nanoparticles are exposed to biological fluids, different endogenous biomolecules can adsorb on their surface forming a biomolecular corona.<sup>233,234</sup> The composition of the corona strongly affects the behavior and fate of the nanoparticles.<sup>235,236</sup> Interestingly, the material core and ligand shell of the nanoparticles can facilitate or (even) prevent the formation of the corona, opening avenues to improve and optimize cell internalization, and biological effects of nanoparticles and nanomedicines.<sup>237,238</sup>

### 6.3. The importance of the model

Another limitation of many toxicological studies (not only omics) is the use of immortal cancer cell lines.<sup>239</sup> These cells are easy to handle since they can continuously grow and divide in laboratory settings. Nevertheless, these cells have unique





**Fig. 4** Proteomic analysis of mouse spermatocyte cells exposed to SiO<sub>2</sub>NPs. In the figure, the control group and the low (12.5  $\mu\text{g mL}^{-1}$ ), middle (25  $\mu\text{g mL}^{-1}$ ), and high (50  $\mu\text{g mL}^{-1}$ ) doses of SiO<sub>2</sub>NPs are abbreviated as C, L, M, and H, respectively. (A) PCA score of the SiO<sub>2</sub>NP-treated group and control group. (B) Several upregulated and downregulated differentially expressed proteins in different groups. (C) Volcano plot of proteins identified after exposure to SiO<sub>2</sub>NPs. (D) Hierarchical clustering heatmap of differentially expressed proteins. Adapted with permission of ref. 224. Copyright Elsevier 2022.

genetic alterations that are not found in normal healthy cells. Hence, they might display characteristics and functions that are not relevant to any cell type *in vivo*. Moreover, after multiple passages, the characteristics of immortal cell lines can change, becoming even more distinct from those of healthy cells. Thus, it is important to validate that the characteristics of the cell model are relevant to the aim of the study. Furthermore, *in vitro* cell models in general are severely limited by their simplicity, which completely ignores the absorption, distribution, metabolism and excretion of the particles.<sup>240,241</sup> For instance, to interact with hepatocytes, nanoparticles need to be absorbed, reach the blood circulation, avoid phagocyte uptake,

extravasate through the endothelial wall and finally reach the hepatic cells. Some nanoparticles are unlikely to reach the final destination, and the cell culture assays would yield artificial results, while other nanoparticles are likely to be transformed through the process.

#### 6.4. The importance of reporting the nanoparticle characteristics

Taken together, the large variability of nanoparticles challenges their toxicological assessment. Conclusions drawn from a toxicomics study using a specific set of nanoparticles may only be valid for that specific set of colloids. Hence, when pub-

lishing toxicological studies, it is very important to properly characterize and report the features of the nanoparticles. Unfortunately, this is not always the case, and key characteristics, such as size or shell composition, are not commonly reported in the literature.

## 7. Conclusion

The prevalent use of inorganic nanoparticles in many human-driven activities requires a thorough assessment of nanoparticle biological impact and safety. Omics approaches, including transcriptomics, epigenetics, proteomics, metabolomics, and lipidomics, are improving our understanding of the molecular effects of nanoparticles, uncovering biological functions disrupted by the nanomaterials, and highlighting genes, proteins and other biomarkers associated with their toxicity. In addition, omics techniques can be used to identify endogenous agents that participate in minimizing the harmful effects of the nanoparticles or to better understand the therapeutic mechanisms associated with nanomedicines. So far, a limited number of studies have explored the use of omics to characterize the toxicity of inorganic nanoparticles, however, we expect that these numbers will increase in the future, as omics studies can support the development of nanoparticles with lower biological impact and yield safer industrial and clinical applications.

## Data availability

No primary research results, software or code have been included and no new data were generated or analysed as part of this review.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

This work was funded by the Federal Ministry of Education and Research (BMBF) and the Ministry of Culture and Science of the German State of North Rhine-Westphalia (MKW) under the Excellence Strategy of the Federal Government and the Länder through the RWTH Junior Principal Investigator (JPI) fellowship scheme.

## References

- X. He, H. Deng and H. Hwang, *J. Food Drug Anal.*, 2019, **27**, 1–21.
- S. Bayda, M. Adeel, T. Tuccinardi, M. Cordani and F. Rizzolio, *Molecules*, 2019, **25**, 112.
- C. Huang, K. G. Neoh, L. Wang, E. Kang and B. Shuter, *Contrast Media Mol. Imaging*, 2011, **6**, 298–307.
- R. Cheng, F. Feng, F. Meng, C. Deng, J. Feijen and Z. Zhong, *J. Controlled Release*, 2011, **152**, 2–12.
- J. Pan, D. Wan and J. Gong, *Chem. Commun.*, 2011, **47**, 3442–3444.
- J. E. Thompson, *J. Occup. Environ. Med.*, 2018, **60**, 392–423.
- F. J. Kelly and J. C. Fussell, *Philos. Trans. R. Soc., A*, 2020, **378**, 20190322.
- C. Guo, S. Robertson, R. J. M. Weber, A. Buckley, J. Warren, A. Hodgson, J. Z. Rappoport, K. Ignatyev, K. Meldrum, I. Römer, S. Macchiarulo, J. K. Chipman, T. Marczylo, M. O. Leonard, T. W. Gant, M. R. Viant and R. Smith, *Nanotoxicology*, 2019, **13**, 733–750.
- A. V. Singh, P. Laux, A. Luch, C. Sudrik, S. Wiehr, A.-M. Wild, G. Santomauro, J. Bill and M. Sitti, *Toxicol. Mech. Methods*, 2019, **29**, 378–387.
- X. Li, W. Liu, L. Sun, K. E. Aifantis, B. Yu, Y. Fan, Q. Feng, F. Cui and F. Watari, *J. Biomed. Mater. Res., Part A*, 2015, **103**, 2499–2507.
- C. Andraos and M. Gulumian, *Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol.*, 2021, **13**, e1680.
- S. Borandeh, V. Alimardani, S. S. Abolmaali and J. Seppälä, *Chem. Res. Toxicol.*, 2021, **34**, 1386–1402.
- Nanotoxicology in Safety Assessment of Nanomaterials*, ed. H. Louro and M. J. Silva, Springer International Publishing, Cham, 2022, vol. 1357.
- E. Fröhlich, *J. Nanobiotechnol.*, 2017, **15**, 84.
- A. Aranda, L. Sequedo, L. Tolosa, G. Quintas, E. Burello, J. V. Castell and L. Gombau, *Toxicol. In Vitro*, 2013, **27**, 954–963.
- A. V. Singh, V. Chandrasekar, N. Paudel, P. Laux, A. Luch, D. Gemmati, V. Tisato, K. S. Prabhu, S. Uddin and S. P. Dakua, *Biomed. Pharmacother.*, 2023, **163**, 114784.
- R. M. Pallares, Y. Li and R. J. Abergel, *TrAC, Trends Anal. Chem.*, 2023, **167**, 117251.
- S.-E. Nam, D.-Y. Bae, J.-S. Ki, C.-Y. Ahn and J.-S. Rhee, *Mol. Cell. Toxicol.*, 2023, **19**, 3–11.
- R. M. Pallares, D. Faulkner, D. D. An, S. Hébert, A. Loguinov, M. Proctor, J. A. Villalobos, K. A. Bjornstad, C. J. Rosen, C. Vulpe and R. J. Abergel, *Proc. Natl. Acad. Sci. U. S. A.*, 2021, **118**, e2025952118.
- M. D. Luque De Castro and R. Quiles-Zafra, *Talanta*, 2020, **219**, 121197.
- R. M. Pallares, D. D. An, S. Hébert, D. Faulkner, A. Loguinov, M. Proctor, J. A. Villalobos, K. A. Bjornstad, C. J. Rosen, C. Vulpe and R. J. Abergel, *Mol. Omics*, 2022, **18**, 237–248.
- R. M. Pallares, D. D. An, S. Hébert, A. Loguinov, M. Proctor, J. A. Villalobos, K. A. Bjornstad, C. J. Rosen, C. D. Vulpe and R. J. Abergel, *ACS Omega*, 2022, **7**, 34412–34419.
- R. M. Pallares, D. D. An, S. Hébert, A. Loguinov, M. Proctor, J. A. Villalobos, K. A. Bjornstad, C. J. Rosen, C. Vulpe and R. J. Abergel, *Metalomics*, 2023, **15**, mfad039.



24 T. Xia, M. Kovochich, J. Brant, M. Hotze, J. Sempf, T. Oberley, C. Sioutas, J. I. Yeh, M. R. Wiesner and A. E. Nel, *Nano Lett.*, 2006, **6**, 1794–1807.

25 S. J. Kang, B. M. Kim, Y. J. Lee and H. W. Chung, *Environ. Mol. Mutagen.*, 2008, **49**, 399–405.

26 S. M. Hussain, K. L. Hess, J. M. Gearhart, K. T. Geiss and J. J. Schlager, *Toxicol. In Vitro*, 2005, **19**, 975–983.

27 E. Fröhlich, *Curr. Drug Metab.*, 2013, **14**, 976–988.

28 A. L. Kersey, T.-U. Nguyen, B. Nayak, I. Singh and A. K. Gaharwar, *Mater. Today*, 2023, **64**, 98–120.

29 *Molecular Profiling: Methods and Protocols*, ed. V. Espina and L. A. Liotta, Humana Press, Totowa, NJ, 2012, vol. 823.

30 Y. Hasin, M. Seldin and A. Lusis, *Genome Biol.*, 2017, **18**, 83.

31 P.-Y. Wu, R. Chandramohan, J. H. Phan, W. T. Mahle, J. W. Gaynor, K. O. Maher and M. D. Wang, *Circ.: Cardiovasc. Genet.*, 2014, **7**, 701–710.

32 R. Hrdlickova, M. Toloue and B. Tian, *WIREs RNA*, 2017, **8**, e1364.

33 R. M. Pallares, E. Jarvis, D. D. An, C. H. Wu, P. Y. Chang and R. J. Abergel, *Environ. Adv.*, 2022, **8**, 100245.

34 Y. Chen, C. Li, C. Tan and X. Liu, *J. Med. Genet.*, 2016, **53**, 359–365.

35 S. P. Barrett and J. Salzman, *Development*, 2016, **143**, 1838–1847.

36 M. W. Feinberg and K. J. Moore, *Circ. Res.*, 2016, **118**, 703–720.

37 B. F. Voight, H. M. Kang, J. Ding, C. D. Palmer, C. Sidore, P. S. Chines, N. P. Burtt, C. Fuchsberger, Y. Li, J. Erdmann, T. M. Frayling, I. M. Heid, A. U. Jackson, T. Johnson, T. O. Kilpeläinen, C. M. Lindgren, A. P. Morris, I. Prokopenko, J. C. Randall, R. Saxena, N. Soranzo, E. K. Speliotes, T. M. Teslovich, E. Wheeler, J. Maguire, M. Parkin, S. Potter, N. W. Rayner, N. Robertson, K. Stirrups, W. Winckler, S. Sanna, A. Mulas, R. Nagaraja, F. Cucca, I. Barroso, P. Deloukas, R. J. F. Loos, S. Kathiresan, P. B. Munroe, C. Newton-Cheh, A. Pfeufer, N. J. Samani, H. Schunkert, J. N. Hirschhorn, D. Altshuler, M. I. McCarthy, G. R. Abecasis and M. Boehnke, *PLoS Genet.*, 2012, **8**, e1002793.

38 S. B. Ng, E. H. Turner, P. D. Robertson, S. D. Flygare, A. W. Bigham, C. Lee, T. Shaffer, M. Wong, A. Bhattacharjee, E. E. Eichler, M. Bamshad, D. A. Nickerson and J. Shendure, *Nature*, 2009, **461**, 272–276.

39 D. C. Koboldt, K. M. Steinberg, D. E. Larson, R. K. Wilson and E. R. Mardis, *Cell*, 2013, **155**, 27–38.

40 J. He and J. Gai, in *Plant Genotyping*, ed. Y. Shavrukov, Springer US, New York, NY, 2023, vol. 2638, pp. 123–146.

41 V. Tam, N. Patel, M. Turcotte, Y. Bossé, G. Paré and D. Meyre, *Nat. Rev. Genet.*, 2019, **20**, 467–484.

42 K. C. Wang and H. Y. Chang, *Circ. Res.*, 2018, **122**, 1191–1199.

43 A. Piunti and A. Shilatifard, *Science*, 2016, **352**, aad9780.

44 R. Barouki, E. Melén, Z. Herceg, J. Beckers, J. Chen, M. Karagas, A. Puga, Y. Xia, L. Chadwick, W. Yan, K. Audouze, R. Slama, J. Heindel, P. Grandjean, T. Kawamoto and K. Nohara, *Environ. Int.*, 2018, **114**, 77–86.

45 M. H. Rabotnick, J. Ehlinger, A. Haidari and J. M. Goodrich, *Mol. Cell. Endocrinol.*, 2023, **578**, 112046.

46 Roadmap Epigenomics Consortium, A. Kundaje, W. Meuleman, J. Ernst, M. Bilenky, A. Yen, A. Heravi-Moussavi, P. Kheradpour, Z. Zhang, J. Wang, M. J. Ziller, V. Amin, J. W. Whitaker, M. D. Schultz, L. D. Ward, A. Sarkar, G. Quon, R. S. Sandstrom, M. L. Eaton, Y.-C. Wu, A. R. Pfenning, X. Wang, M. Claussnitzer, Y. Liu, C. Coarfa, R. A. Harris, N. Shores, C. B. Epstein, E. Gjoneska, D. Leung, W. Xie, R. D. Hawkins, R. Lister, C. Hong, P. Gascard, A. J. Mungall, R. Moore, E. Chuah, A. Tam, T. K. Canfield, R. S. Hansen, R. Kaul, P. J. Sabo, M. S. Bansal, A. Carles, J. R. Dixon, K.-H. Farh, S. Feizi, R. Karlic, A.-R. Kim, A. Kulkarni, D. Li, R. Lowdon, G. Elliott, T. R. Mercer, S. J. Neph, V. Onuchic, P. Polak, N. Rajagopal, P. Ray, R. C. Sallari, K. T. Siebenthal, N. A. Sinnott-Armstrong, M. Stevens, R. E. Thurman, J. Wu, B. Zhang, X. Zhou, A. E. Beaudet, L. A. Boyer, P. L. De Jager, P. J. Farnham, S. J. Fisher, D. Haussler, S. J. M. Jones, W. Li, M. A. Marra, M. T. McManus, S. Sunyaev, J. A. Thomson, T. D. Tlsty, L.-H. Tsai, W. Wang, R. A. Waterland, M. Q. Zhang, L. H. Chadwick, B. E. Bernstein, J. F. Costello, J. R. Ecker, M. Hirst, A. Meissner, A. Milosavljevic, B. Ren, J. A. Stamatoyannopoulos, T. Wang and M. Kellis, *Nature*, 2015, **518**, 317–330.

47 Z. Zhang, S. Wu, D. L. Stenøien and L. Paša-Tolić, *Annu. Rev. Anal. Chem.*, 2014, **7**, 427–454.

48 T. Rabilloud and P. Lescuyer, *Proteomics*, 2015, **15**, 1051–1074.

49 T. Qiao and X. Wang, *Cell Biol. Toxicol.*, 2019, **35**, 289–291.

50 R. J. Rotello and T. D. Veenstra, *Curr. Protein Pept. Sci.*, 2021, **22**, 121–133.

51 H. Zhu, M. Bilgin and M. Snyder, *Annu. Rev. Biochem.*, 2003, **72**, 783–812.

52 W. Li and N. B. Caberoy, *Appl. Microbiol. Biotechnol.*, 2010, **85**, 909–919.

53 A. Paiano, A. Margiotta, M. De Luca and C. Bucci, *Curr. Protoc. Protein Sci.*, 2019, **95**, e70.

54 D. Tsikas, *Amino Acids*, 2021, **53**, 485–487.

55 Z. W. Lai, Y. Yan, F. Caruso and E. C. Nice, *ACS Nano*, 2012, **6**, 10438–10448.

56 Y. Zhang, B. R. Fonslow, B. Shan, M.-C. Baek and J. R. Yates, *Chem. Rev.*, 2013, **113**, 2343–2394.

57 T. Chen, J. Zhao, J. Ma and Y. Zhu, *Genomics, Proteomics Bioinf.*, 2015, **13**, 36–39.

58 M. P. Monopoli, D. Walczyk, A. Campbell, G. Elia, I. Lynch, F. Baldelli Bombelli and K. A. Dawson, *J. Am. Chem. Soc.*, 2011, **133**, 2525–2534.

59 R. Bilardo, F. Traldi, A. Vdovchenko and M. Resmini, *Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol.*, 2022, **14**, e1788.



60 S. J. Park, *Int. J. Nanomed.*, 2020, **15**, 5783–5802.

61 V. Pareek, A. Bhargava, V. Bhanot, R. Gupta, N. Jain and J. Panwar, *J. Nanosci. Nanotechnol.*, 2018, **18**, 6653–6670.

62 F. Pederzoli, G. Tosi, M. A. Vandelli, D. Belletti, F. Forni and B. Ruozzi, *Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol.*, 2017, **9**, e1467.

63 W. Wohlleben, M. D. Driessens, S. Raesch, U. F. Schaefer, C. Schulze, B. V. Vacano, A. Vennemann, M. Wiemann, C. A. Ruge, H. Platsch, S. Mues, R. Ossig, J. M. Tomm, J. Schnekenburger, T. A. J. Kuhlbusch, A. Luch, C.-M. Lehr and A. Haase, *Nanotoxicology*, 2016, **10**, 970–980.

64 S. Schöttler, G. Becker, S. Winzen, T. Steinbach, K. Mohr, K. Landfester, V. Mailänder and F. R. Wurm, *Nat. Nanotechnol.*, 2016, **11**, 372–377.

65 C. Pisani, J.-C. Gaillard, M. Odorico, J. L. Nyaloasoso, C. Charnay, Y. Guari, J. Chopineau, J.-M. Devoisselle, J. Armengaud and O. Prat, *Nanoscale*, 2017, **9**, 1840–1851.

66 K. D. La Luz-Hdez, in *Metabolomics*, ed. U. Roessner, InTech, 2012.

67 R. T. McKay, in *Metabolomics and Its Impact on Health and Diseases*, ed. V. Ghini, K. A. Stringer and C. Luchinat, Springer International Publishing, Cham, 2022, vol. 277, pp. 73–116.

68 G. A. Nagana Gowda and D. Raftery, in *Cancer Metabolomics*, ed. S. Hu, Springer International Publishing, Cham, 2021, vol. 1280, pp. 19–37.

69 J. L. Markley, R. Brüschweiler, A. S. Edison, H. R. Eghbalnia, R. Powers, D. Raftery and D. S. Wishart, *Curr. Opin. Biotechnol.*, 2017, **43**, 34–40.

70 A.-H. Emwas, R. Roy, R. T. McKay, L. Tenori, E. Saccenti, G. A. N. Gowda, D. Raftery, F. Alahmari, L. Jaremko, M. Jaremko and D. S. Wishart, *Metabolites*, 2019, **9**, 123.

71 W. B. Dunn, D. I. Broadhurst, H. J. Atherton, R. Goodacre and J. L. Griffin, *Chem. Soc. Rev.*, 2011, **40**, 387–426.

72 R. Madsen, T. Lundstedt and J. Trygg, *Anal. Chim. Acta*, 2010, **659**, 23–33.

73 G. J. Patti, O. Yanes and G. Siuzdak, *Nat. Rev. Mol. Cell Biol.*, 2012, **13**, 263–269.

74 X. Han and R. W. Gross, *J. Lipid Res.*, 2022, **63**, 100164.

75 H. F. Avela and H. Sirén, *Clin. Chim. Acta*, 2020, **510**, 123–141.

76 D. Masuero, D. Škrab, G. Chitarrini, M. Garcia-Aloy, P. Franceschi, P. Sivilotti, G. Guella and U. Vrhovsek, *Metabolites*, 2021, **11**, 827.

77 J. A. Adeyemi, C. A. Sorgi, A. R. T. Machado, A. T. Ogunjimi, L. G. A. Gardinassi, V. Nardini, L. H. Faccioli, L. M. G. Antunes and F. Barbosa, *Arch. Toxicol.*, 2020, **94**, 2625–2636.

78 R. M. Pallares, N. T. K. Thanh and X. Su, *Nanoscale*, 2019, **11**, 22152–22171.

79 B. Klebowski, J. Depciuch, M. Parlińska-Wojtan and J. Baran, *Int. J. Mol. Sci.*, 2018, **19**, 4031.

80 G. Doria, J. Conde, B. Veigas, L. Giestas, C. Almeida, M. Assunção, J. Rosa and P. V. Baptista, *Sensors*, 2012, **12**, 1657–1687.

81 M. Azharuddin, G. H. Zhu, D. Das, E. Ozgur, L. Uzun, A. P. F. Turner and H. K. Patra, *Chem. Commun.*, 2019, **55**, 6964–6996.

82 S. Li, M. Meng Lin, M. S. Toprak, D. K. Kim and M. Muhammed, *Nano Rev.*, 2010, **1**, 5214.

83 C. J. Murphy, T. K. Sau, A. M. Gole, C. J. Orendorff, J. Gao, L. Gou, S. E. Hunyadi and T. Li, *J. Phys. Chem. B*, 2005, **109**, 13857–13870.

84 R. M. Pallares, F. Kiessling and T. Lammers, *Nanomedicine*, 2023, **18**, 413–416.

85 J. Langer, D. Jimenez De Aberasturi, J. Aizpurua, R. A. Alvarez-Puebla, B. Auguié, J. J. Baumberg, G. C. Bazan, S. E. J. Bell, A. Boisen, A. G. Brolo, J. Choo, D. Cialla-May, V. Deckert, L. Fabris, K. Faulds, F. J. García De Abajo, R. Goodacre, D. Graham, A. J. Haes, C. L. Haynes, C. Huck, T. Itoh, M. Käll, J. Kneipp, N. A. Kotov, H. Kuang, E. C. Le Ru, H. K. Lee, J.-F. Li, X. Y. Ling, S. A. Maier, T. Mayerhöfer, M. Moskovits, K. Murakoshi, J.-M. Nam, S. Nie, Y. Ozaki, I. Pastoriza-Santos, J. Perez-Juste, J. Popp, A. Pucci, S. Reich, B. Ren, G. C. Schatz, T. Shegai, S. Schlücker, L.-L. Tay, K. G. Thomas, Z.-Q. Tian, R. P. Van Duyne, T. Vo-Dinh, Y. Wang, K. A. Willets, C. Xu, H. Xu, Y. Xu, Y. S. Yamamoto, B. Zhao and L. M. Liz-Marzán, *ACS Nano*, 2020, **14**, 28–117.

86 D. T. Thompson, *Nano Today*, 2007, **2**, 40–43.

87 I. Saldan, Y. Semenyuk, I. Marchuk and O. Reshetnyak, *J. Mater. Sci.*, 2015, **50**, 2337–2354.

88 I. Kriegel, F. Scotognella and L. Manna, *Phys. Rep.*, 2017, **674**, 1–52.

89 R. Zhang, F. Kiessling, T. Lammers and R. M. Pallares, *Drug Delivery Transl. Res.*, 2023, **13**, 378–385.

90 Y. Liu, W. Ma and J. Wang, *Curr. Pharm. Des.*, 2018, **24**, 2719–2728.

91 W. Li and X. Chen, *Nanomedicine*, 2015, **10**, 299–320.

92 L. Danai, L. A. Rolband, V. A. Perdomo, E. Skelly, T. Kim and K. A. Afonin, *Nanomedicine*, 2023, **18**, 769–782.

93 M. Alavi, *Expert Rev. Anti-Infect. Ther.*, 2022, **20**, 897–906.

94 T. Bruna, F. Maldonado-Bravo, P. Jara and N. Caro, *Int. J. Mol. Sci.*, 2021, **22**, 7202.

95 A. R. Ghosh, A. N. Bhooshitha, H. M. Chandan and K. L. Krishna, *Indian J. Pharm. Educ. Res.*, 2021, **55**, 319–329.

96 S. Park, Y.-S. Ko, S. J. Lee, C. Lee, K. Woo and G. Ko, *Environ. Sci. Pollut. Res.*, 2018, **25**, 27021–27030.

97 P. Velmurugan, S.-M. Lee, M. Cho, J.-H. Park, S.-K. Seo, H. Myung, K.-S. Bang and B.-T. Oh, *Appl. Microbiol. Biotechnol.*, 2014, **98**, 8179–8189.

98 B. S. Atiyeh, M. Costagliola, S. N. Hayek and S. A. Dibo, *Burns*, 2007, **33**, 139–148.

99 F. L. Filon, M. Mauro, G. Adamo, M. Bovenzi and M. Crosera, *Regul. Toxicol. Pharmacol.*, 2015, **72**, 310–322.

100 J. Ma, X. Lü and Y. Huang, *J. Biomed. Nanotechnol.*, 2011, **7**, 263–275.

101 Y. Huang, X. Lü and J. Ma, *J. Biomed. Nanotechnol.*, 2014, **10**, 3304–3317.



102 J. Carrola, V. Bastos, I. Jarak, R. Oliveira-Silva, E. Malheiro, A. L. Daniel-da-Silva, H. Oliveira, C. Santos, A. M. Gil and I. F. Duarte, *Nanotoxicology*, 2016, **10**, 1105–1117.

103 S. Bakand, A. Hayes and F. Dechsakulthorn, *Inhalation Toxicol.*, 2012, **24**, 125–135.

104 S. Sonwani, S. Madaan, J. Arora, S. Suryanarayanan, D. Rangra, N. Mongia, T. Vats and P. Saxena, *Front. Sustainable Cities*, 2021, **3**, 690444.

105 R. Foldbjerg, E. S. Irving, Y. Hayashi, D. S. Sutherland, K. Thorsen, H. Autrup and C. Beer, *Toxicol. Sci.*, 2012, **130**, 145–157.

106 J. Jang, S. Park and I.-H. Choi, *Biomolecules*, 2021, **11**, 234.

107 R. M. Pallares, F. M. Mottaghay, V. Schulz, F. Kiessling and T. Lammers, *J. Nucl. Med.*, 2022, **63**, 1802–1808.

108 Y.-N. Zhang, W. Poon, A. J. Tavares, I. D. McGilvray and W. C. W. Chan, *J. Controlled Release*, 2016, **240**, 332–348.

109 K. Kawata, M. Osawa and S. Okabe, *Environ. Sci. Technol.*, 2009, **43**, 6046–6051.

110 Q.-Q. Xiang, Y.-H. Kang, L.-H. Lian, Z.-Y. Chen, P. Wang, J.-M. Hu and L.-Q. Chen, *Aquat. Toxicol.*, 2022, **252**, 106318.

111 S.-F. Thai, C. P. Jones, B. L. Robinette, H. Ren, B. Vallanat, A. A. Fisher and K. T. Kitchin, *J. Nanosci. Nanotechnol.*, 2021, **21**, 5414–5428.

112 S. Gioria, P. Urbán, M. Hajduch, P. Barboro, N. Cabaleiro, R. La Spina and H. Chassaigne, *Toxicol. In Vitro*, 2018, **50**, 347–372.

113 K. Williams, J. Milner, M. D. Boudreau, K. Gokulan, C. E. Cerniglia and S. Khare, *Nanotoxicology*, 2015, **9**, 279–289.

114 X.-L. Wang, N. Yu, C. Wang, H.-R. Zhou, C. Wu, L. Yang, S. Wei and A.-J. Miao, *ACS Nano*, 2022, **16**, 19002–19012.

115 S. Wang, X. Kang, H. Alenius, S. H. Wong, P. Karisola and H. El-Nezami, *Food Chem. Toxicol.*, 2022, **169**, 113368.

116 B. Cui, L. Ren, Q.-H. Xu, L.-Y. Yin, X.-Y. Zhou and J.-X. Liu, *Aquat. Toxicol.*, 2016, **177**, 295–305.

117 C. Lu, Y. Lv, G. Kou, Y. Liu, Y. Liu, Y. Chen, X. Wu, F. Yang, J. Luo and X. Yang, *Ecotoxicol. Environ. Saf.*, 2022, **243**, 113993.

118 R. Sardar, A. M. Funston, P. Mulvaney and R. W. Murray, *Langmuir*, 2009, **25**, 13840–13851.

119 R. M. Pallares, X. Su, S. H. Lim and N. T. K. Thanh, *J. Mater. Chem. C*, 2016, **4**, 53–61.

120 R. Zhang, F. Kiessling, T. Lammers and R. M. Pallares, *J. Phys. Chem. C*, 2022, **126**, 18580–18585.

121 *Colloidal synthesis of plasmonic nanometals*, ed. L. M. Liz-Marzán, Jenny Stanford Publishing, Singapore, 2020.

122 Z. Xi, R. Zhang, F. Kiessling, T. Lammers and R. M. Pallares, *ACS Biomater. Sci. Eng.*, 2024, **10**, 38–50.

123 E. C. Dreaden, A. M. Alkilany, X. Huang, C. J. Murphy and M. A. El-Sayed, *Chem. Soc. Rev.*, 2012, **41**, 2740–2779.

124 R. Zhang, S. Thoröe-Bovleth, D. N. Chigrin, F. Kiessling, T. Lammers and R. M. Pallares, *J. Nanobiotechnol.*, 2024, **22**, 115.

125 Z. Xi, R. Zhang, S. Thoröe-Bovleth, F. Kiessling, T. Lammers and R. M. Pallares, *ACS Appl. Nano Mater.*, 2023, **6**, 17336–17346.

126 J. Zhang, G. Chen, D. Guay, M. Chaker and D. Ma, *Nanoscale*, 2014, **6**, 2125–2130.

127 Y. Huang, X. Lü, Y. Qu, Y. Yang and S. Wu, *Biomaterials*, 2015, **37**, 13–24.

128 M. Hu, C. Wen, J. Liu, P. Cai, N. Meng, X. Qin, P. Xu, Z. Li and X.-C. Lin, *ACS Appl. Bio Mater.*, 2023, **6**, 1886–1895.

129 B. Nikoobakht and M. A. El-Sayed, *Chem. Mater.*, 2003, **15**, 1957–1962.

130 H.-H. Chang and C. J. Murphy, *Chem. Mater.*, 2018, **30**, 1427–1435.

131 R. M. Pallares, Y. Wang, S. H. Lim, N. T. K. Thanh and X. Su, *Nanomedicine*, 2016, **11**, 2845–2860.

132 S. Stolik, J. A. Delgado, A. Pérez and L. Anasagasti, *J. Photochem. Photobiol. B*, 2000, **57**, 90–93.

133 C. Deraedt and D. Astruc, *Acc. Chem. Res.*, 2014, **47**, 494–503.

134 S. Sounderajan, G. Kiran Kumar, S. A. Kumar, A. C. Udas and G. Venkateswaran, *Talanta*, 2009, **78**, 1122–1128.

135 D. Astruc, C. Ornelas and J. Ruiz, *Acc. Chem. Res.*, 2008, **41**, 841–856.

136 U. Lange, T. Hirsch, V. M. Mirsky and O. S. Wolfbeis, *Electrochim. Acta*, 2011, **56**, 3707–3712.

137 M. Song, N. Liu, L. He, G. Liu, D. Ling, X. Su and X. Sun, *Nano Res.*, 2018, **11**, 2796–2808.

138 M. Chen, S. Chen, C. He, S. Mo, X. Wang, G. Liu and N. Zheng, *Nano Res.*, 2017, **10**, 1234–1248.

139 L. Nie, M. Chen, X. Sun, P. Rong, N. Zheng and X. Chen, *Nanoscale*, 2014, **6**, 1271–1276.

140 X. Huang, S. Tang, X. Mu, Y. Dai, G. Chen, Z. Zhou, F. Ruan, Z. Yang and N. Zheng, *Nat. Nanotechnol.*, 2011, **6**, 28–32.

141 S. Gurunathan, M. Qasim, C. H. Park, M. Arsalan Iqbal, H. Yoo, J. H. Hwang, S. J. Uhm, H. Song, C. Park, Y. Choi, J.-H. Kim and K. Hong, *Nanomaterials*, 2019, **9**, 787.

142 Y. Zhou, G. He, H. Jiang, K. Pan and W. Liu, *Environ. Int.*, 2023, **174**, 107899.

143 I. Iavicoli, M. Farina, L. Fontana, D. Lucchetti, V. Leso, C. Fanali, V. Cufino, A. Boninsegna, K. Leopold, R. Schindl, D. Brucker and A. Sgambato, *Toxicol. In Vitro*, 2017, **42**, 191–199.

144 J. Liang, N. Li, Z. Zhao, L. Ma, X. Wang, S. Li, X. Liu, T. Wang, Y. Du, G. Lu, J. Han, Y. Huang, D. Su and Q. Li, *Angew. Chem., Int. Ed.*, 2019, **58**, 15471–15477.

145 W. Si, Y. Yin, D. Cao, Y. Hu, X. Kang, J. Liu, X. Wang, Y. Xu, R. Yang and Q. Gu, *Constr. Build. Mater.*, 2022, **340**, 127700.

146 H. Xu, L.-L. He, Y.-F. Pei, C.-Z. Jiang, W.-Q. Li and X.-H. Xiao, *Tungsten*, 2021, **3**, 20–37.

147 H. Türkez, M. E. Arslan, E. Sönmez, A. Tatar, M. Açıkyıldız and F. Geyikoglu, *Chem.-Biol. Interact.*, 2017, **273**, 257–265.

148 M. Jeyaraj, S. Gurunathan, M. Qasim, M.-H. Kang and J.-H. Kim, *Nanomaterials*, 2019, **9**, 1719.

149 S. McFarlane, C. P. K. Manchee, J. W. Silverstone, J. Veinot and A. Meldrum, *J. Visualized Exp.*, 2013, 50256.

150 Md. A. R. Khan, M. S. A. Mamun and M. H. Ara, *Microchem. J.*, 2021, **171**, 106840.



151 D. Pedone, M. Moglianetti, E. De Luca, G. Bardi and P. P. Pompa, *Chem. Soc. Rev.*, 2017, **46**, 4951–4975.

152 P. V. Asharani, Y. Lianwu, Z. Gong and S. Valiyaveettil, *Nanotoxicology*, 2011, **5**, 43–54.

153 R. E. Doherty, I. V. Sazanovich, L. K. McKenzie, A. S. Stasheuski, R. Coyle, E. Baggaley, S. Bottomley, J. A. Weinstein and H. E. Bryant, *Sci. Rep.*, 2016, **6**, 22668.

154 Z. Wang, L. Chen, C. Huang, Y. Huang and N. Jia, *J. Mater. Chem. B*, 2017, **5**, 3498–3510.

155 S. Gurunathan, M. Jeyaraj, H. La, H. Yoo, Y. Choi, J. T. Do, C. Park, J.-H. Kim and K. Hong, *Int. J. Mol. Sci.*, 2020, **21**, 440.

156 M. S. Chavali and M. P. Nikolova, *SN Appl. Sci.*, 2019, **1**, 607.

157 J. A. Makawana, C. B. Sangani, Y.-F. Yao, Y.-T. Duan, P.-C. Lv and H.-L. Zhu, *Mini-Rev. Med. Chem.*, 2016, **16**, 1303–1320.

158 E. Lee, Y. S. Yoon and D.-J. Kim, *ACS Sens.*, 2018, **3**, 2045–2060.

159 Y. Ren, W. Xie, Y. Li, J. Ma, J. Li, Y. Liu, Y. Zou and Y. Deng, *ACS Cent. Sci.*, 2021, **7**, 1885–1897.

160 M. Rahman, *Nanotheranostics*, 2023, **7**, 424–449.

161 H. Y. Son, B. I. Koo, J. B. Lee, K. R. Kim, W. Kim, J. Jang, M. S. Yoon, J.-W. Cho and Y. S. Nam, *ACS Appl. Mater. Interfaces*, 2018, **10**, 27344–27354.

162 S. Li, W. Yin, Y. Li, J. Sun, M. Zhu, Z. Liu and T. Deng, *Nanoscale*, 2019, **11**, 14912–14920.

163 L. C. Mohr, A. P. Capelezzo, C. R. D. M. Baretta, M. A. P. M. Martins, M. A. Fiori and J. M. M. Mello, *Polym. Test.*, 2019, **77**, 105867.

164 T. G. Smijs and S. Pavel, *Nanotechnol. Sci. Appl.*, 2011, **4**, 95–112.

165 A. Ayati, A. Ahmadpour, F. F. Bamoharram, B. Tanhaei, M. Mänttäri and M. Sillanpää, *Chemosphere*, 2014, **107**, 163–174.

166 S. Villa, V. Caratto, F. Locardi, S. Alberti, M. Sturini, A. Speltini, F. Maraschi, F. Canepa and M. Ferretti, *Materials*, 2016, **9**, 771.

167 C.-Y. Wu, K.-J. Tu, J.-P. Deng, Y.-S. Lo and C.-H. Wu, *Materials*, 2017, **10**, 566.

168 M.-C. Wu, K.-C. Hsiao, Y.-H. Chang and K. Kordás, *ACS Appl. Nano Mater.*, 2019, **2**, 1970–1979.

169 K. Fujita, M. Horie, H. Kato, S. Endoh, M. Suzuki, A. Nakamura, A. Miyauchi, K. Yamamoto, S. Kinugasa, K. Nishio, Y. Yoshida, H. Iwahashi and J. Nakanishi, *Toxicol. Lett.*, 2009, **191**, 109–117.

170 S. Montalvo-Quiros and J. L. Luque-Garcia, *Food Chem. Toxicol.*, 2019, **127**, 197–205.

171 M. Husain, A. T. Saber, C. Guo, N. R. Jacobsen, K. A. Jensen, C. L. Yauk, A. Williams, U. Vogel, H. Wallin and S. Halappanavar, *Toxicol. Appl. Pharmacol.*, 2013, **269**, 250–262.

172 B. Li, Y. Ze, Q. Sun, T. Zhang, X. Sang, Y. Cui, X. Wang, S. Gui, D. Tan, M. Zhu, X. Zhao, L. Sheng, L. Wang, F. Hong and M. Tang, *PLoS One*, 2013, **8**, e55563.

173 Y. Ma, Y. Guo, H. Ye, K. Huang, Z. Lv and Y. Ke, *Ecotoxicol. Environ. Saf.*, 2019, **176**, 1–10.

174 D. D. Deobagkar, N. Patil and W. N. Gade, *Int. J. Nanomed.*, 2016, **11**, 4509–4519.

175 A. B. Herman, D. Tsitsipatis and M. Gorospe, *Mol. Cell*, 2022, **82**, 2252–2266.

176 S. Panni, R. C. Lovering, P. Porras and S. Orchard, *Biochim. Biophys. Acta, Gene Regul. Mech.*, 2020, **1863**, 194417.

177 J. Shi, Y. Zhang, Y. Ma, Z. Chen and G. Jia, *Toxics*, 2022, **10**, 724.

178 J. Jiang, J. Pi and J. Cai, *Bioinorg. Chem. Appl.*, 2018, **2018**, 1–18.

179 K. Girigoswami, M. Viswanathan, R. Murugesan and A. Girigoswami, *Mater. Sci. Eng., C*, 2015, **56**, 501–510.

180 S. V. Gudkov, D. E. Burmistrov, D. A. Serov, M. B. Rebezov, A. A. Semenova and A. B. Lisitsyn, *Front. Phys.*, 2021, **9**, 641481.

181 P. Fan, D. Zhang, Y. Wu, J. Yu and T. P. Russell, *Adv. Funct. Mater.*, 2020, **30**, 2002932.

182 J. M. Fine, T. Gordon, L. C. Chen, P. Kinney, G. Falcone and W. S. Beckett, *J. Occup. Environ. Med.*, 1997, **39**, 722–726.

183 L. C. Rohrs, *Arch. Intern. Med.*, 1957, **100**, 44.

184 N. Hadrup, F. Rahmani, N. R. Jacobsen, A. T. Saber, P. Jackson, S. Bengtson, A. Williams, H. Wallin, S. Halappanavar and U. Vogel, *Nanotoxicology*, 2019, **13**, 1275–1292.

185 X. Pei, H. Jiang, G. Xu, C. Li, D. Li and S. Tang, *Int. J. Mol. Sci.*, 2022, **23**, 6724.

186 X. Wang, S. Chen, Y. Qin, H. Wang, Z. Liang, Y. Zhao, L. Zhou and C. J. Martyniuk, *Aquat. Toxicol.*, 2022, **253**, 106333.

187 H. H. Gustafson, D. Holt-Casper, D. W. Grainger and H. Ghandehari, *Nano Today*, 2015, **10**, 487–510.

188 Z. Doumandji, R. Safar, M. Lovera-Leroux, S. Nahle, H. Cassidy, D. Matallanas, B. Rihn, L. Ferrari and O. Joubert, *Cell Biol. Toxicol.*, 2020, **36**, 65–82.

189 R. Jin, B. Lin, D. Li and H. Ai, *Curr. Opin. Pharmacol.*, 2014, **18**, 18–27.

190 C. Blanco-Andujar, A. Walter, G. Cotin, C. Bordeianu, D. Mertz, D. Felder-Flesch and S. Begin-Colin, *Nanomedicine*, 2016, **11**, 1889–1910.

191 Y. Li, R. Zhang, R. Barmin, E. Rama, M. Schoenen, F. Schrank, V. Schulz, I. Slabu, F. Kiessling, T. Lammers and R. M. Pallares, *Nanoscale Adv.*, 2024, DOI: [10.1039/D4NA00378K](https://doi.org/10.1039/D4NA00378K).

192 H. Nogueira, S. Toma, A. Silveira Jr. and K. Araki, *J. Braz. Chem. Soc.*, 2020, **31**, 11.

193 A. Kumar, G. Sharma, M. Naushad and S. Thakur, *Chem. Eng. J.*, 2015, **280**, 175–187.

194 N. Singh, G. J. S. Jenkins, R. Asadi and S. H. Doak, *Nano Rev.*, 2010, **1**, 5358.

195 R. S. Bonadio, M. Cunha, J. P. F. Longo, R. B. Azevedo and M. J. Poças-Fonseca, *J. Nanosci. Nanotechnol.*, 2020, **20**, 1454–1462.

196 P. C. Ke, S. Lin, W. J. Parak, T. P. Davis and F. Caruso, *ACS Nano*, 2017, **11**, 11773–11776.



197 L. Xia, S. Alqahtani, C. R. Ferreira, U. K. Aryal, K. Biggs and J. H. Shannahan, *Nanomaterials*, 2022, **12**, 2022.

198 C. Sun, H. Li and L. Chen, *Energy Environ. Sci.*, 2012, **5**, 8475.

199 A. Nemmar, S. Al-Salam, S. Beegam, P. Yuvaraju and B. Ali, *Biomolecules*, 2019, **9**, 376.

200 S. De, S. Mohanty and S. K. Nayak, *Bioprocess Biosyst. Eng.*, 2015, **38**, 1671–1683.

201 S. Chaudhary, P. Sharma, D. Singh, A. Umar and R. Kumar, *ACS Sustainable Chem. Eng.*, 2017, **5**, 6803–6816.

202 S. Balaji, B. K. Mandal, L. Vinod Kumar Reddy and D. Sen, *Bioengineering*, 2020, **7**, 26.

203 R. M. Pallares, S. L. Karstens, T. Arino, A. M. Minor and R. J. Abergel, *ACS Appl. Nano Mater.*, 2023, **6**, 8141–8145.

204 G. Lu, H. Zheng, J. Lv, G. Wang and X. Huang, *J. Power Sources*, 2020, **480**, 229091.

205 S. Verstraelen, S. Remy, E. Casals, P. De Boever, H. Witters, A. Gatti, V. Puntes and I. Nelissen, *Toxicol. Lett.*, 2014, **228**, 157–169.

206 X. He, Z. R. Jarrell, M. R. Smith, V. T. Ly, Y. Liang, M. Orr, Y.-M. Go and D. P. Jones, *Toxicol. Appl. Pharmacol.*, 2023, **459**, 116327.

207 P. R. Suma, R. A. Padmanabhan, S. R. Telukutla, R. Ravindran, A. K. G. Velikkakath, C. D. Dekiwadia, W. Paul, M. Laloraya, S. M. Srinivasula, S. V. Bhosale and R. S. Jayasree, *Free Radicals Biol. Med.*, 2020, **161**, 198–211.

208 A. R. Gliga, S. Di Buccianico, E. Åkerlund and H. L. Karlsson, *Nanomaterials*, 2020, **10**, 649.

209 B. Yu, X. Lu, X. Feng, T. Zhao, J. Li, Y. Lu, F. Ye, X. Liu, X. Zheng, Z. Shen, X. Jin, W. Chen and Q. Li, *Int. J. Nanomed.*, 2023, **18**, 7713–7728.

210 R. Frick, B. Müller-Edenborn, A. Schlicker, B. Rothen-Rutishauser, D. O. Raemy, D. Günther, B. Hattendorf, W. Stark and B. Beck-Schimmer, *Toxicol. Lett.*, 2011, **205**, 163–172.

211 G. M. Saladino, B. Brodin, R. Kakadiya, M. S. Toprak and H. M. Hertz, *Sci. Adv.*, 2024, **10**, eadl2267.

212 S. M. Reimann and M. Manninen, *Rev. Mod. Phys.*, 2002, **74**, 1283–1342.

213 J. Wu, S. Chen, A. Seeds and H. Liu, *J. Phys. D: Appl. Phys.*, 2015, **48**, 363001.

214 R. E. Bailey, A. M. Smith and S. Nie, *Phys. E*, 2004, **25**, 1–12.

215 R. M. Pallares, P. Agbo, X. Liu, D. D. An, S. S. Gauny, S. E. Zeltmann, A. M. Minor and R. J. Abergel, *ACS Appl. Mater. Interfaces*, 2020, **12**, 40078–40084.

216 S. Jafari, H. Derakhshankhah, L. Alaei, A. Fattahi, B. S. Varnamkhasti and A. A. Saboury, *Biomed. Pharmacother.*, 2019, **109**, 1100–1111.

217 S. Porrang, S. Davaran, N. Rahemi, S. Allahyari and E. Mostafavi, *Int. J. Nanomed.*, 2022, **17**, 1803–1827.

218 N. K. Tarasova, A. Gallud, A. J. Ytterberg, A. Chernobrovkin, J. R. Aranzaes, D. Astruc, A. Antipov, Y. Fedutik, B. Fadeel and R. A. Zubarev, *J. Proteome Res.*, 2017, **16**, 689–697.

219 F. Akhter, A. A. Rao, M. N. Abbasi, S. A. Wahcho, M. A. Mallah, H. Anees-ur-Rehman and Z. A. Chandio, *Silicon*, 2022, **14**, 8295–8310.

220 T. I. Janjua, Y. Cao, C. Yu and A. Popat, *Nat. Rev. Mater.*, 2021, **6**, 1072–1074.

221 M. Iftikhar, A. Noureen, M. Uzair, F. Jabeen, M. Abdel Daim and T. Cappello, *Int. J. Environ. Res. Public Health*, 2021, **18**, 1758.

222 J.-P. Klein, L. Mery, D. Boudard, C. Ravel, M. Cottier and D. Bitounis, *Int. J. Mol. Sci.*, 2022, **24**, 576.

223 G. Zhou, L. Ren, H. Yin, J. Liu, X. Li, J. Wang, Y. Li, Y. Sang, Y. Zhao, X. Zhou and Z. Sun, *NanoImpact*, 2021, **23**, 100348.

224 Y. Zhu, Y. Zhang, Y. Li, C. Guo, Z. Fan, Y. Li, M. Yang, X. Zhou, Z. Sun and J. Wang, *J. Hazard. Mater.*, 2022, **434**, 128820.

225 H. S. Choi, W. Liu, P. Misra, E. Tanaka, J. P. Zimmer, B. I. Ipe, M. G. Bawendi and J. V. Frangioni, *Nat. Biotechnol.*, 2007, **25**, 1165–1170.

226 Z. Yu, Q. Li, J. Wang, Y. Yu, Y. Wang, Q. Zhou and P. Li, *Nanoscale Res. Lett.*, 2020, **15**, 115.

227 R. Mohammadpour and H. Ghandehari, *Adv. Drug Delivery Rev.*, 2022, **180**, 114022.

228 K. Bhattacharjee and B. L. V. Prasad, *Chem. Soc. Rev.*, 2023, **52**, 2573–2595.

229 E. Fröhlich, *Int. J. Nanomed.*, 2012, 5577.

230 C. He, Y. Hu, L. Yin, C. Tang and C. Yin, *Biomaterials*, 2010, **31**, 3657–3666.

231 J. Mosquera, I. García and L. M. Liz-Marzán, *Acc. Chem. Res.*, 2018, **51**, 2305–2313.

232 D. Docter, D. Westmeier, M. Markiewicz, S. Stolte, S. K. Knauer and R. H. Stauber, *Chem. Soc. Rev.*, 2015, **44**, 6094–6121.

233 M. Hadjideimetrou and K. Kostarelos, *Nat. Nanotechnol.*, 2017, **12**, 288–290.

234 E. Casals and V. F. Puntes, *Nanomedicine*, 2012, **7**, 1917–1930.

235 T. Kopac, *Int. J. Biol. Macromol.*, 2021, **169**, 290–301.

236 C. C. Fleischer and C. K. Payne, *Acc. Chem. Res.*, 2014, **47**, 2651–2659.

237 G. Caracciolo, S. Palchetti, V. Colapicchioni, L. Digiocomo, D. Pozzi, A. L. Capriotti, G. La Barbera and A. Laganà, *Langmuir*, 2015, **31**, 10764–10773.

238 V. Palmieri and G. Caracciolo, *Nanoscale Adv.*, 2022, **4**, 3300–3308.

239 M. Carter and J. Shieh, in *Guide to Research Techniques in Neuroscience*, Elsevier, 2015, pp. 295–310.

240 L. Yuan, Q. Chen, J. E. Riviere and Z. Lin, *J. Drug Delivery Sci. Technol.*, 2023, **83**, 104404.

241 A. Zhang, K. Meng, Y. Liu, Y. Pan, W. Qu, D. Chen and S. Xie, *Adv. Colloid Interface Sci.*, 2020, **284**, 102261.

